0001520138-19-000474.txt : 20191119 0001520138-19-000474.hdr.sgml : 20191119 20191119153536 ACCESSION NUMBER: 0001520138-19-000474 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 44 CONFORMED PERIOD OF REPORT: 20190930 FILED AS OF DATE: 20191119 DATE AS OF CHANGE: 20191119 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOVIE INC. CENTRAL INDEX KEY: 0001580149 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 462510769 STATE OF INCORPORATION: NV FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-39015 FILM NUMBER: 191231015 BUSINESS ADDRESS: STREET 1: 2120 COLORADO AVE. STREET 2: SUITE 230 CITY: LOS ANGELES STATE: CA ZIP: 90404 BUSINESS PHONE: 310-444-4300 MAIL ADDRESS: STREET 1: 2120 COLORADO AVE. STREET 2: SUITE 230 CITY: LOS ANGELES STATE: CA ZIP: 90404 FORMER COMPANY: FORMER CONFORMED NAME: NANOANTIBIOTICS, INC. DATE OF NAME CHANGE: 20130625 10-Q 1 bivi-20190930_10q.htm FORM 10-Q FOR PERIOD ENDING SEPT 30, 2019

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

(Mark One)

☒

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: September 30, 2019

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____________to _____________

Commission File Number: 001-39015

BIOVIE INC.

(Exact name of registrant as specified in its charter)

Nevada		46-2510769
(State or other jurisdiction of incorporation or organization)		(I.R.S. Empl. Ident. No.)

2120 Colorado Avenue Suite 230

Santa Monica, CA 90404

(Address of principal executive offices, Zip Code)

(310)-444-4300

(Registrant's telephone number, including area code)

(Former Name, Former Address and Former Fiscal Year if Changed Since Last Report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No ☒

There were 647,930,147 shares of the Registrant’s $0.0001 par value Class A common stock outstanding as of November 18, 2019.

TABLE OF CONTENTS

PART I – FINANCIAL INFORMATION

Item 1.	Financial Statements	1
	Condensed Balance Sheets at September 30, 2019 (unaudited) and June 30, 2019	1
	Condensed Statements of Operations (unaudited) - for the three months ended September 30, 2019 and 2018	2
	Condensed Statements of Cash Flows (unaudited) - for the three months ended September 30, 2019 and 2018	3
	Condensed Statements of Changes in Stockholders’ (Deficit) Equity (unaudited) - for the three months ended September 30, 2018 and 2019	4
	Notes to Unaudited Condensed Financial Statements	5
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	17
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	20
Item 4.	Controls and Procedures	20

PART II – OTHER INFORMATION

Item 1.	Legal Proceedings	21
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	21
Item 3.	Defaults Upon Senior Securities	21
Item 4.	Mine Safety Disclosures	21
Item 5.	Other Information	21
Item 6.	Exhibits	22

SIGNATURES		23

FORWARD-LOOKING STATEMENTS

This report contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, and Section 27A of the Securities Act of 1933. Any statements contained in this report that are not statements of historical fact may be forward-looking statements. When we use the words “intends,” “estimates,” “predicts,” “potential,” “continues,” “anticipates,” “plans,” “expects,” “believes,” “should,” “could,” “may,” “will” or the negative of these terms or other comparable terminology, we are identifying forward-looking statements. Forward-looking statements involve risks and uncertainties, which may cause our actual results, performance or achievements to be materially different from those expressed or implied by forward-looking statements. These factors include our research and development activities, distributor channel; compliance with regulatory impositions; and our capital needs. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

Except as may be required by applicable law, we do not undertake or intend to update or revise our forward-looking statements, and we assume no obligation to update any forward-looking statements contained in this report as a result of new information or future events or developments. Thus, you should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. You should carefully review and consider the various disclosures we make in this report and our other reports filed with the Securities and Exchange Commission that attempt to advise interested parties of the risks, uncertainties and other factors that may affect our business.

All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law. When used in this report, the terms “BioVie”, “Company”, “we”, “our”, and “us” refer to BioVie Inc.

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

BioVie Inc.

Condensed Balance Sheets

	September 30,			June 30,
	2019			2019
ASSETS	(Unaudited)

CURRENT ASSETS:
Cash	$	249,009		$	339,923
Other assets		516,379			334,150
Total current assets		765,388			674,073

OTHER ASSETS:
Intangible assets, net		1,497,259			1,554,603
Goodwill		345,711			345,711
Total other assets		1,842,970			1,900,314

TOTAL ASSETS	$	2,608,358		$	2,574,387

LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES:
Accounts payable and accrued expenses	$	684,060		$	443,480
Derivative liability - warrants		8,109,724			—
Derivative liability - conversion option on convertible debenture		2,533,668			—
Convertible debenture - related party, net of discount $498,466 and $0 at September 30, 2019 and 2018, respectively		1,534			—
Total current liabilities		11,328,986			443,480

Commitments and contingencies (Note 8)

STOCKHOLDERS' (DEFICIT) EQUITY

Preferred stock; $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding		—			—
Common stock, $0.0001 par value; 800,000,000 shares authorized at September 30, 2019 and June 30, 2019, respectively; 647,930,147 and 507,305,147 shares issued and outstanding at September 30, 2019 and June 30, 2019, respectively		64,793			50,730
Additional paid in capital		19,396,936			9,342,249
Accumulated deficit		(28,182,357	)		(7,262,072	)
Total stockholders' (deficit) equity		(8,720,628	)		2,130,907

TOTAL LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY	$	2,608,358		$	2,574,387

See accompanying notes to unaudited condensed financial statements

-1-

Table of Contents

BioVie Inc.

Condensed Statements of Operations

(Unaudited)

	Three Months Ended
	September 30, 2019			September 30, 2018
OPERATING EXPENSES:
Amortization	$	57,344		$	57,344
Research and development expenses		341,501			194,521
Selling, general and administrative expenses		307,373			239,562
TOTAL OPERATING EXPENSES		706,218			491,427

LOSS FROM OPERATIONS		(706,218	)		(491,427	)

OTHER EXPENSE (INCOME):
Change in fair value of derivative liabilities		(362,586	)		—
Gain on settlement of debt		—			(51,400	)
Interest expense		3,477,615			272
Interest income		(20	)		(428	)
TOTAL OTHER EXPENSE (INCOME), NET		3,115,009			(51,556	)


NET LOSS	$	(3,821,227	)	$	(439,871	)

Deemed dividends for commitment shares and rachet adjustments		17,099,058			48,659

NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	$	(20,920,285	)	$	(488,530	)

NET LOSS PER COMMON SHARE - BASIC AND DILUTED	$	(0.04	)	$	(0.00	)

WEIGHTED AVERAGE NUMBER OF
COMMON SHARES OUTSTANDING - BASIC AND DILUTED		516,577,125			309,279,009

See accompanying notes to unaudited condensed financial statements

-2-

Table of Contents

BioVie Inc.

Condensed Statements of Cash Flows

(Unaudited)

	Three Months Ended
	September 30, 2019			September 30, 2018

CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(3,821,227	)	$	(439,871	)
Adjustments to reconcile net loss to net cash to cash used in operating activities:
Amortization of intangible assets		57,344			57,344
Stock based compensation expense		—			3,412
Interest expense from convertible debenture		3,477,204			—
Change in fair value of derivative liabilities		(362,586	)		—
Changes in operating assets and liabilities
Other assets		(182,229	)		—
Accounts payable and accrued expenses		240,580			(62,767	)
Net cash used in operating activities		(590,914	)		(441,882	)

CASH FLOWS FROM FINANCING ACTIVITIES:
Repayment of debt		—			(508,300	)
Proceeds from issuance of preferred shares		—			3,040,000
Proceeds from convertible debenture - related party		500,000
Net cash provided by financing activities		500,000			2,531,700

Net (decrease) increase in cash		(90,914	)		2,089,818

Cash, beginning of period		339,923			45,800

Cash, end of period	$	249,009		$	2,135,619

SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for interest	$	411		$	—
Cash paid for taxes	$	—		$	—

SCHEDULE OF NON-CASH FINANCING ACTIVITIES:
Conversion of preferred shares to common stock	$	—		$	3,200,000
Settlement of debt by issuance of common stock and forgiveness of debt	$	—		$	1,150,135
Cashless exercise of warrants	$	—		$	224
Deemed dividends for ratchet adjustments to warrants	$	—		$	48,659
Deemed dividends for commitment shares	$	17,099,058			—
Stock warrants classified as derivative liability	$	7,530,308			—

See accompanying notes to unaudited condensed financial statements

-3-

Table of Contents

BioVie Inc.

Condensed Statements of Changes in Stockholders’ (Deficit) Equity

For the Three Months Ended September 30, 2018 and 2019

(Unaudited)

											Additional						Total Stockholders’
	Preferred Stock						Common Stock				Paid in			Accumulated			Equity
	Shares			Amount			Shares		Amount		Capital			Deficit			(Deficit)
Balance, June 30, 2018		—		$	—			98,503,199	$	9,850	$	4,870,474		$	(4,769,126	)	$	111,199

Issuance of preferred stock in a private placement		2,133,332			3,200,000			—		—		3,200,000			—			3,200,000

Conversion of preferred stock to common stock		(2,133,332	)		(3,200,000	)		213,333,200		21,333		(21,333	)		—			—

Issuance of shares in exchange for debt settlement		—			—			975,361		98		1,150,037			—			1,150,135

Stock option compensation		—			—			—		—		3,412			—			3,412

Cashless exercise of warrants		—			—			2,241,913		224		(224	)		—			—

Deemed dividends for ratchet adjustment to warrants		—			—			—		—		48,659			(48,659	)		—

Net loss		—			—			—		—		—			(439,871	)		(439,871	)

Balance, September 30, 2018		—		$	—			315,053,673	$	31,505	$	9,251,025		$	(5,257,655	)	$	4,024,876


Balance June 30, 2019		—		$	—			507,305,147	$	50,730	$	9,342,249		$	(7,262,072	)	$	2,130,907

Issuance of commitment shares		—			—			140,625,000		14,063		10,054,687			—			10,068,750

Deemed dividend for commitment shares		—			—			—		—		—			(17,099,058	)		(17,099,058	)

Net loss		—			—			—		—		—			(3,821,227	)		(3,821,227	)

Balance, September 30, 2019		—		$	—			647,930,147	$	64,793	$	19,396,936		$	(28,182,357	)	$	(8,720,628	)

See accompanying notes to unaudited condensed financial statements

-4-

Table of Contents

BIOVIE INC.

Notes to Condensed Financial Statements

For the Three Months Ended September 30, 2019 and 2018

(unaudited)

1.	Background Information

BioVie Inc. (the “Company”) is a clinical-stage company pursuing the discovery, development, and commercialization of innovative drug therapies. We are currently focused on developing and commercializing BIV201 (continuous infusion terlipressin), a novel approach to the treatment of ascites due to chronic liver cirrhosis. Our therapy BIV201 is based on a drug that is approved in about 40 countries to treat related complications of liver cirrhosis (part of the same disease pathway as ascites), but not yet available in the United States. BIV201’s active agent is a potent vasoconstrictor and has shown efficacy for reducing portal hypertension in studies around the world. The goal is for BIV201 to interrupt the ascites disease pathway, thereby halting the cycle of accelerating fluid generation in ascites patients.

BioVie began administering BIV201 to patients in a Phase 2a clinical trial in patients with refractory ascites due to advanced liver cirrhosis at the McGuire Research Institute Inc. in Richmond, VA in September 2017. In April 2019, we announced top-line results and in June met with representatives of the FDA for a Type C Guidance Meeting to discuss the study results and plan our next clinical study. In July 2019, the FDA provided meeting minutes that documented general agreement with the Company’s proposed randomized and controlled study design. The FDA also provided its suggestions and guidance regarding primary and secondary endpoints, quality of life measures and other key aspects of the clinical trial design. In October 2019, BioVie announced the submission of a Phase 2b/3 clinical trial protocol to the FDA. We are developing a patent-pending novel liquid formulation of terlipressin for use in this study that is intended to improve convenience for outpatient administration and avoid potential formulation errors that may occur when pharmacists reconstitute the powder version.

BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, nonalcoholic steatohepatitis (NASH), and alcoholism. It has FDA Fast-Track status and Orphan Drug designation for the most common of these complications, ascites, which represents a significant unmet medical need. An Orphan drug that is first-to-market typically receives 7 years of market exclusivity in the United States for the designated use(s). The FDA has never approved any drug specifically for treating ascites. In addition, the Company has a pending patent application directed to proprietary liquid formulations of terlipressin for use in its planned Phase 2b/3 trial, subject to FDA clearance, which could eventually provide up to 20 years of patent coverage in each country in which the Company seeks patent protection, such as the United States, if a patent issues according to the patent laws of the issuing country.

The BIV201 development program began at LAT Pharma LLC. On April 11, 2016, the Company acquired LAT Pharma LLC and the rights to its BIV201 development program. The Company currently owns all development and marketing rights to its drug candidate. The Company and PharmaIN, Corp. (“PharmaIN”), LAT Pharma’s former partner focused on the development of new modified drug candidates in the same therapeutic field but not including BIV201, had agreed to pay royalties equal to less than 1% of future net sales of each company's ascites drug development programs, or if such program is licensed to a third party, less than 5% of each company's net license revenues. On December 24, 2018, the Company returned its partial ownership rights to the PharmaIN modified terlipressin development program and simultaneously paid the remaining balance due on a related debt. PharmaIN, Corp.’s rights to our program remain unchanged.

The Company’s activities are subject to significant risks and uncertainties including failure to secure additional funding to properly execute the Company’s business plan.

-5-

Table of Contents

BIOVIE INC.

Notes to Condensed Financial Statements

For the Three Months Ended September 30, 2019 and 2018

(unaudited)

2.	Liquidity and Going Concern

The Company’s operations are subject to a number of factors that can affect its operating results and financial conditions. Such factors include, but are not limited to: the results of clinical testing and trial activities of the Company’s products, the Company’s ability to obtain regulatory approval to market its products, competition from products manufactured and sold or being developed by other companies, the price of, and demand for, Company products, the Company’s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, and the Company’s ability to raise capital. The Company’s financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As of September 30, 2019, the Company had an accumulated deficit of $28.2 million and as a development stage enterprise, the Company expects substantial losses in future periods. The accompanying interim financial statements were prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company’s future operations are dependent on the success of the Company’s ongoing development and commercialization effort, as well as continuing to secure additional financing.

On September 24, 2019, the Company entered into a Securities Purchase Agreement with its controlling stockholder regarding bridge financing (the “Bridge Financing”) in the form of up to $2.0 million in convertible debt and warrants, of which $500,000 has been drawn as of September 30, 2019. Amounts borrowed under the Bridge Financing must be repaid with the proceeds of our potential public offering of equity securities referred to below. The availability of additional draws under the Bridge Financing is under further discussion with the controlling stockholder in light of delays in the timing of the potential public offering. As further discussed below, the Company is pursuing various options to raise further financing to continue the testing and development of its product. If the Company is not successful in raising additional funds it may reduce its monthly spend and potentially delay the implementation of the larger scale Phase 2b Clinical trial until sufficient funding is secured.

Additionally, in April 2019, to facilitate our planned up listing to the NASDAQ Stock Market and related potential future issuances and sales of our equity securities for ordinary corporate finance and general corporate purposes and as recommended by our Board of Directors (“Board”), our stockholders approved an amendment to our Articles of Incorporation to effect a reverse split of our outstanding Class A common stock in the range of 50:1 to 200:1, as determined by our Board. Following that approval, we filed a Registration Statement on Form S-1 (Registration No. 333-231136) (the “S-1 Registration Statement”) pursuant to which we anticipate completing an offering of our equity securities with proceeds sufficient to enable the launch and completion of the BIV201 Phase 2b study and fund our internal operations for at least the next twelve months. There can be no assurance, however, that we will successfully complete an offering thereunder on the terms contemplated by the S-1 Registration Statement or on any commercially reasonable terms.

The future viability of the Company is largely dependent upon its ability to raise additional capital to finance its operations. Management expects that future sources of funding may include sales of equity, obtaining loans, or other strategic transactions. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient financing on terms acceptable to the Company, if at all, to fund continuing operations. These circumstances raise substantial doubt on the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

-6-

Table of Contents

BIOVIE INC.

Notes to Condensed Financial Statements

For the Three Months Ended September 30, 2019 and 2018

(unaudited)

3.	Significant Accounting Policies

Basis of Presentation – Interim Financial Information

The accompanying unaudited interim financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United State of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities Exchange Commission for Interim Reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring accruals) that are, in the opinion of management, considered necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. The condensed balance sheet at June 30, 2019 was derived from audited annual financial statements but does not contain all the footnote disclosures from the annual financial statements. The accompanying financial statements and information included under the heading: “Management’s Discussion and Analysis of Financial Condition and Results of Operations” should be read in conjunction with our Company’s audited financial statements and related notes included in our Company’s Form 10-K for the year ended June 30, 2019 filed with the SEC on September 27, 2019.

For a summary of significant accounting policies, see the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2019 filed with the SEC on September 27, 2019.

Net Loss per Common Share

Basic net loss per common share is computed by dividing the net loss before deemed dividend by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding and potentially outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants, convertible preferred stock and convertible debentures. Due to the net loss for the period, such amounts were excluded from the diluted loss since their effect was considered anti-dilutive.

The table below shows the number of outstanding stock options and warrants as of September 30, 2019 and 2018:

	September 30, 2019		September 30, 2018
	Number of Shares		Number of Shares
Stock Options		7,250,000		5,150,000
Warrants		171,833,216		216,441,548
Total		179,083,216		221,591,548

Recent accounting pronouncements

The Company considers the applicability and impact of all Accounting Standard Updates (“ASU’s”). ASU’s not discussed below were assessed and determined to be either not applicable or expected to have minimal impact on our balance sheets or statement of operations.

-7-

Table of Contents

BIOVIE INC.

Notes to Condensed Financial Statements

For the Three Months Ended September 30, 2019 and 2018

(unaudited)

3.	Significant Accounting Policies (continued)

In June 2018, the FASB issued ASU 2018-07, “Compensation – Stock Compensation (Topic 718): Improvements to Non-employee Share-Based Accounting”. This guidance aligns the accounting for share-based payment transactions with non-employees to accounting for share-based payment transactions with employees. Companies are required to record a cumulative-effect adjustment (net of tax) to retained earnings as of the beginning of the fiscal year of the adoption. Upon transition, non-employee awards are required to be measured at fair value as of the adoption date. This standard will be effective for fiscal years beginning December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. The Company has adopted this ASU as of July 1, 2019. There has been no impact on the financial statements.

In August 2018, the FASB issued ASU 2018-13, “Fair value measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement”. The new guidance modifies the disclosure requirements on fair value measurements. ASU 2018-13 is effective for fiscal years beginning after December 15, 2019. Early adoption is permitted. The Company does not expect ASU 2018-13 to have a significant impact to its condensed consolidated financial statements and related disclosures.

4.	Intangible Assets

The Company’s intangible assets consist of intellectual property acquired from LAP Pharma, Inc. and are amortized over their estimated useful lives. The following is a summary of the intangible assets as of September 30, 2019 and June 30, 2019:

	September 30, 2019			June 30, 2019

Intellectual Property	$	2,293,770		$	2,293,770
Less Accumulated Amortization		(796,511	)		(739,167	)
Intellectual Property, Net	$	1,497,259		$	1,554,603

Amortization expense for the three-month period ended September 30, 2019 and 2018 was $57,344 and $57,344 respectively.

Estimated future amortization expense is as follows:

Year ending June 30, 2020 (Remaining nine months)	$ 172,032
2021	229,377
2022	229,377
2023	229,377
2024	229,377
2025	229,377
Thereafter	178,342
	$ 1,497,259

-8-

Table of Contents

BIOVIE INC.

Notes to Condensed Financial Statements

For the Three Months Ended September 30, 2019 and 2018

(unaudited)

5.	Related Party Transactions

Equity Transactions with Acuitas

On July 3, 2018, we entered into a Securities Purchase Agreement (the “Purchase Agreement”) with Acuitas Group Holding, LLC (“Acuitas”) and certain other purchasers identified in the Purchase Agreement (together with Acuitas, the “Purchasers”) pursuant to which (i) the Purchasers agreed to purchase an aggregate of 2,133,332 shares of the our Series A Convertible Preferred Stock (the “Preferred Stock”) at a price per share of $1.50 per share of Preferred Stock (the “Initial Sale”) and (ii) we agreed to issue warrants (the “Warrants”) to purchase 213,333,200 shares of common stock, each subject to the terms and conditions set forth in the Purchase Agreement, for an aggregate consideration of $3.2 million. We received $160,000 of the $3.2 million in April and May 2018 as prepaid equity. Acuitas also received an additional 833,333 Warrants in connection with the payoff of a note issued by us in favor of Acuitas. The Initial Sale and issuance of the Warrants occurred on July 3, 2018. In addition, Acuitas had the option to purchase up to an additional 200,000,000 shares of common stock at a price per share of $0.015, and warrants on the same terms as the Warrants, within two weeks following the one year anniversary of the closing of the Initial Sale (the “Subsequent Sale”) in the event that we did not obtain $3,000,000 of funding through various non-dilutive grants prior to the one year anniversary of the closing of the Initial Sale, less any federal or FDA grant funding received by the Company. Acuitas is controlled by our Chairman and Chief Executive Officer, Terren Peizer and the Purchasers included Jonathan Adams, James Lang, Cuong Do and Michael Sherman, who are members of our Board.

The Purchase Agreement contained customary representations and warranties. In connection with the disclosure schedule associated with the representations and warranties, we also disclosed customary information, including the following: (i) the existence of the Mallinckrodt petition before the U.S. Patent Trial and Appeal Board, (ii) our capitalization, (iii) our obligation to pay a low single digit royalty on the net sales of BIV201 (continuous infusion terlipressin) to be shared among LAT Pharma LLC members, PharmaIN Corporation and The Barrett Edge, Inc. pursuant to the Agreement and Plan of Merger, dated April 11, 2016, by and between LAT Pharma LLC and us, (iv) our obligation to pay a low single digit royalty on net sales of all terlipressin products covered by specified patents up to a maximum of $200,000 per year pursuant to the Technology Transfer Agreement, dated July 25, 2016, by and between us and the University of Padova (Italy), and (v) certain recent issuances of common stock by us.

Each share of Preferred Stock automatically converted into 100 shares of common stock upon the filing with the Secretary of State of the State of Nevada of a Certificate of Amendment to our Articles of Incorporation (the “Amendment”) on August 13, 2018 that increased the number of authorized shares of common stock to 800,000,000. The Amendment was approved by the written consent of the holders of more than a majority of our issued and outstanding common stock on July 3, 2018 and was filed with the Secretary of State of the State of Nevada 20 calendar days following the distribution of our Definitive Information Statement on Schedule 14 that was filed with the SEC on July 13, 2018.

Pursuant to a letter agreement dated June 24, 2019, Acuitas agreed to modify its existing rights under the Purchase Agreement so that:

Acuitas agreed to immediately exchange its existing 200,833,333 Warrants for common stock such that it will have effectively exercised its Warrants in full pursuant to a cashless exercise thereof at an assumed current market price of $0.36 per share and, as a result received an aggregate of 95% of the shares covered thereby, or 190,761,666 shares of common stock;

-9-

Table of Contents

BIOVIE INC.

Notes to Condensed Financial Statements

For the Three Months Ended September 30, 2019 and 2018

(unaudited)

5.	Related Party Transactions (continued)

Acuitas agreed to (i) waive its rights to a 50% adjustment of the purchase price of the Preferred Stock in the Initial Sale, the exercise price of the Warrants and the price per share in the Subsequent Sale in the event of certain reductions in the useful life of our current intellectual property rights, and (ii) effectively exercise its rights to purchase securities in a Subsequent Sale pursuant to a “cashless purchase” at an assumed current market price of approximately $0.09 per share, conditioned in each case on the listing of our common stock on Nasdaq or the raising of $2.0 million in additional funds in the form of another securities offering, in either case not later than November 30, 2019, which will result Acuitas having irrevocably waived its rights to an adjustment in the purchase price of the Preferred Stock in the Initial Sale and the exercise price of the Warrants and the purchase price of per share in the Subsequent Sale upon the issuance by us of an aggregate of 167,494,750 shares of common stock (the “Subsequent Sale Shares”) to Acuitas, which is expected to occur concurrently with the closing of our potential public offering and listing on Nasdaq;

Acuitas shall in exchange for the foregoing agreements and waivers have the option to purchase additional shares of common stock and warrants to purchase one share of common stock for each share of common stock purchased during the period from September 1, 2019 to November 30, 2019 at the then-effective purchase price of the Preferred Stock in the Initial Sale (the “Funding Option”), provided that any shares issued pursuant to any exercise of the Funding Option will reduce share-for-share the amount of shares issued pursuant to the deemed exercise of its rights to purchase securities in a Subsequent Sale mentioned above.

Convertible Debenture Transaction with Acuitas

On September 24, 2019, the Company entered into a Securities Purchase Agreement (the “2019 Purchase Agreement”) with Acuitas pursuant to which (i) Acuitas agreed to purchase a 10% OID Convertible Delayed Draw Debenture (the “Debenture”) due September 24, 2020 for an aggregate commitment amount of up to $2.0 million, and (ii) the Company issued 140,625,000 shares (the “Commitment Shares”) of the Company’s common stock and warrants (the “Commitment Warrants”) to purchase an equal number of shares, each subject to the terms and conditions set forth in the 2019 Purchase Agreement. The Debenture accrues additional principal at the rate of 6% per annum and interest at the rate of 10% per annum, is convertible into shares of common stock at $0.032 per share prior to the completion of the company’s planned public offering of units (the “Public Offering”) or, subsequent to the closing of the Public Offering, the lower of $0.032 or 80% of the offering price per unit to the public in the Public Offering and are mandatorily redeemable upon such closing at 100% of the accrued principal amount and unpaid interest to the date of redemption. The Commitment Warrants are five-year warrants, exercisable upon the earlier of the effectiveness of the Company’s currently pending reverse stock split or December 1, 2019, at an amount equal to the lower of $0.032 or 80% of the offering price per unit to the public in the Public Offering. Upon entering into the 2019 Purchase Agreement, the Company drew an initial $500,000 under the Debenture and in accordance with the 2019 Purchase Agreement, Acuitas received an additional 15,625,000 warrants (the “Bridge Warrants”) having the same terms as the Commitment Warrants. Any future draws under the Debenture, which may be made from and after October 15, 2019, November 15, 2019 and December 15, 2019 in equal tranches of $500,000 each, will entitle Acuitas to receive additional Bridge Warrants in equal amount upon such funding. In addition, the 2019 Purchase Agreement provides that, should the underwriters in the Public Offering exercise their option to purchase additional securities during the 45 days following closing and the issuance of such securities would result in Acuitas' beneficial ownership (on a fully diluted basis) of shares of common stock being below 60%, Acuitas shall be issued a number of additional shares of common stock and warrants having the same terms as the Commitment Warrants to result in its beneficial ownership (on a fully diluted basis) of shares of common stock equaling 60%.

The issuance of 140,625,000 shares of the Company’s commons stock and warrants to purchase an equal amount number of shares, to its controlling stockholder for the Bridge Financing was accounted for as a deemed dividend due to its related party nature and $17.1 million representing the excess of the fair value of the consideration given for the financing, net of debt discount; was recorded in accumulated deficit for the three months ended September 30, 2019, accordingly. (See accompanied Condensed Statements of Changes in Stockholders’ (Deficit) Equity). A debt discount of $500,000 against the debenture was recorded which will be amortized over the term of the debenture using the effective interest method. The Company recognized amortization of this discount in the amount of $1,534 for the three-month period ended September 30, 2019.

-10-

Table of Contents

BIOVIE INC.

Notes to Condensed Financial Statements

For the Three Months Ended September 30, 2019 and 2018

(unaudited)

5.	Related Party Transactions (continued)

Pursuant to the 2019 Purchase Agreement, Acuitas has agreed to further modify its existing rights under the Purchase Agreement dated July 3, 2018 with the Company so that Acuitas’ previous agreement in June 2019 to waive its rights to a 50% adjustment of the purchase price of the Preferred Stock in the July 2018 transaction, the exercise price of the warrants in such transaction and the price per share in a Subsequent Sale in the event of certain reductions in the useful life of our current intellectual property rights, and effectively exercise its rights to purchase securities in a Subsequent Sale pursuant to a “cashless purchase” at an assumed current market price of approximately $0.09 per share, conditioned in each case on the listing of the Company’s common stock on Nasdaq or the raising of $2.0 million in additional funds in the form of another securities offering, in either case not later than November 30, 2019, such that Acuitas will have irrevocably waived its rights to an adjustment in the purchase price of the Preferred Stock in the Initial Sale and the exercise price of the Warrants and the purchase price of per share in the Subsequent Sale upon the issuance by us of an aggregate of 334,989,500 shares of common stock and 334,989,500 warrants having the same terms as the Commitment Warrants to Acuitas, upon the closing of the Public Offering.

Pursuant to an amendment to the 2019 Purchase Agreement dated October 9, 2019, Acuitas agreed to modify its existing rights under the 2019 Purchase Agreement so that:

The Commitment Warrants (and related warrants issued upon the first draw under the Debenture) were replaced with warrants having similar terms, but which are automatically exercised upon the closing of the offering at an exercise price equal to the par value of the common stock;

Acuitas' existing rights under the Purchase Agreement dated July 3, 2018 with the Company were further amended so that the number of Subsequent Sale Shares would be multiplied by four (in lieu of the changes to the Purchase Agreement originally provided for in the 2019 Purchase Agreement); and

The provisions of the 2019 Purchase Agreement providing that, should the underwriters in the offering exercise their option to purchase additional securities during the 45 days following closing and the issuance of such securities would result in Acuitas’ beneficial ownership (on a fully diluted basis) of shares of common stock being below 60%, Acuitas will be issued a number of additional shares of common stock and warrants having the same terms as the Commitment Warrants to result in its beneficial ownership (on a fully diluted basis) of shares of common stock equaling 60% have been modified such that, upon the exercise of such option by the underwriters, the Company will issue to Acuitas a number of securities that will result in Acuitas’ fully diluted beneficial ownership after the exercise of such option being the same as prior thereto.

(See Note 9 Subsequent Events.)

-11-

Table of Contents

BIOVIE INC.

Notes to Condensed Financial Statements

For the Three Months Ended September 30, 2019 and 2018

(unaudited)

6.	Fair Value Measurements

At September 30, 2019, the estimated fair value of derivative liabilities measured on a recurring basis are as follows:

	Fair Value Measurements at
	September 30, 2019
	Level 1		Level 2		Level 3		Total

Derivative liability - Warrants	$	—	$	—	$	8,109,724	$	8,109,724
Derivative liability -Conversion option on convertible debenture		—		—		2,533,668		2,533,668
Total derivatives	$	—	$	—	$	10,643,392	$	10,643,392

The following table presents the activity for liabilities measured at fair value using unobservable inputs for the three months ended September 30, 2019:

	Derivative liabilities - Warrants			Derivative liability - Conversion Option on Convertible Debenture

Beginning balance at July 1, 2019	$	—		$	—
Additions to level 3 liabilities		8,367,012			2,638,966
Change in in fair value of level 3 liability		(257,288	)		(105,298	)
Transfer in and/or out of Level 3		—			—
Balance at September 30, 2019	$	8,109,724		$	2,533,668

Derivative liability – Warrants

The Company accounts for stock purchase warrants as either equity instruments or derivative liabilities depending on the specific terms of the warrant agreements. Under applicable accounting guidance, stock warrants that are precluded from being indexed to the Company’s own stock because of full-rachet anti-dilution provisions or the adjustments to the strike price due to an occurrence of a future event; are accounted for as derivative financial instruments. The stock warrants issued September 24, 2019 were not considered indexed to the Company’s own stock because of the adjustment to strike price, an occurrence of a future event such as the Company’s pending capital raise.

-12-

Table of Contents

BIOVIE INC.

Notes to Condensed Financial Statements

For the Three Months Ended September 30, 2019 and 2018

(unaudited)

6.	Fair Value Measurements (continued)

The warrants associated with the level 3 liability were issued on September 24, 2019 and were valued using the Black-Scholes-Merton model with the following assumptions: stock price of $0.0716, exercise price of $0.032, term of 5 years expiring September 2024, volatility of 71.44%, dividend yield of 0%, and risk-free interest rate of 1.52%. The valuation at September 30, 2019 used the following assumptions: stock price of $0.0698, exercise price of $0.032, term of 5 year expiring September 2024, volatility of 71.42%, dividend yield of 0%, and risk-free interest rate of 1.55%. (See note 5 “Related Party Transactions – Convertible debenture transactions”)

Derivative liability – Conversion option in convertible debenture

The Company valued the conversion option of the $2 million 10% OID Convertible Delayed Draw Debenture which may be convertible into shares of common stock at $0.032 per share prior to the completion of an offering or, subsequent to the closing of the offering, the lower of $0.032 or 80% of the offering price per unit to the public in this offering and are mandatorily redeemable upon such closing at 100% of the accrued principal amount and unpaid interest to the date of redemption. (See note 5 “Related Party Transactions – Convertible debenture transactions with Acuitas” as of September 24, 2019). The conversion option was valued on September 24, 2019 using the Black Scholes-Mertons model with the following assumptions: stock price of $0.0716, conversion price of $0.032, term of 1 year expiring September 2020, volatility of 75.48%, dividend yield of 0%, and risk-free interest rate of 1.78%. The valuation at September 30, 2019 used the following assumptions: stock price of $0.0698, conversion price of $0.032, term of 1 year expiring September 2020, volatility of 75.5%, dividend yield of 0%, and risk-free interest rate of 1.75%.

7.	Equity Transactions

Stock Options

The following table summarizes the activity relating to the Company’s stock options for the three months ended September 30, 2019:

	Options		Weighted-Average Exercise Price		Weighted Remaining Average Contractual Term		Aggregate Intrinsic Value
Outstanding at June 30, 2019		7,250,000	$	0.10		5.2	$	87,480
Granted		—		—		—		—
Options Exercised or Forfeited		—		—		—		—
Outstanding at September 30, 2019		7,250,000	$	0.10		4.8	$	87,480
Exercisable at September 30, 2019		7,250,000	$	0.10		4.8	$	87,480

-13-

Table of Contents

BIOVIE INC.

Notes to Condensed Financial Statements

For the Three Months Ended September 30, 2019 and 2018

(unaudited)

7.	Equity Transactions (continued)

The fair value of each option grant on the date of grant is estimated using the Black-Scholes option. There were no options granted during the three months ended September 30, 2019. The pricing model reflected the following weighted-average assumptions for the three months ended September 30, 2018:

	September 30 2019		September 30 2018
Expected life of options (In years)		—		9.5
Expected volatility		—		63.09	%
Risk free interest rate		—		0.00	%
Dividend Yield		—		0	%

Expected volatility is based on the historical volatilities of three comparable companies of the daily closing price of their respective common stock and the expected life of options is based on historical data with respect to employee exercise periods. The Company accounts for forfeitures as they are incurred.

The Company recorded stock-based compensation expense of $0 and $3,412 for the three- month period ended September 30, 2019 and 2018, respectively.

The following is a summary of stock options outstanding and exercisable by exercise price as of September 30, 2019:

Exercise Price		Outstanding		Weighted Average Contract Life		Exercisable
$	0.03		700,000		4.3		700,000
$	0.05		1,300,000		4.4		1,300,000
$	0.06		3,100,000		6.4		3,100,000
$	0.07		100,000		4.0		100,000
$	0.10		500,000		3.3		500,000
$	0.20		200,000		3.0		200,000
$	0.21		550,000		2.6		550,000
$	0.22		100,000		2.5		100,000
$	0.23		200,000		2.9		200,000
$	0.25		500,000		2.1		500,000
	Total		7,250,000				7,250,000

Stock Warrants

The following table summarizes the warrants activity during the three months ended September 30, 2019:

	Number of Shares		Weighted Average Exercise Price		Weighted Average Remaining Life (Years)		Aggregate Intrinsic Value
Outstanding and exercisable at June 30, 2019		15,583,216	$	0.36		5.6	$	716,653
Granted		156,250,000	$	0.03		5.0	$	5,906,250
Expired		—	$	—		—	$	—
Outstanding and exercisable at September 30, 2019		171,833,216	$	0.04		4.9	$	6,622,903

Of the above warrants, 1,173,864 expire in fiscal year ending June 30, 2022, 556,818 expire in fiscal year ending June 30, 2023, and 170,102,534 expire in fiscal year ending June 30, 2025.

-14-

Table of Contents

BIOVIE INC.

Notes to Condensed Financial Statements

For the Three Months Ended September 30, 2019 and 2018

(unaudited)

8.	Commitments and Contingencies

Office Lease

On July 1, 2019, the Company’s office moved with Acuitas’ new offices to 2120 Colorado Avenue Ste 230, Santa Monica, CA 90404. There is no lease agreement for the new premises and the Company continues to accrue monthly lease payments of $1,000 for the new office under the terms of the previous month-to-month lease for the previous premises which may be cancelled upon 30 days’ written notice.

Challenge to US Patent

On April 30, 2018, we received notice that Mallinckrodt had petitioned the U.S. Patent and Trademark Office (“USPTO”) to institute an Inter Partes Review of our U.S. Patent No. 9,655,945 titled “Treatment of Ascites” (the “’945 patent”). Inter Partes Review is a trial proceeding conducted with the USPTO Patent Trial and Appeal Board (PTAB) to review the patentability of one or more claims of a patent. Such review is limited to grounds of novelty and obviousness on the basis of prior art consisting of patents and printed publications.

On November 13, 2019, the Patent Trial and Appeal Board of the United States Patent and Trademark Office (the “Board”) issued a written decision in the inter partes review (“IPR”) action that was brought by Mallinckrodt Pharmaceuticals Ireland Limited (“Mallinckrodt”) against BioVie Inc. (“BioVie” or “Company”). In that action, Mallinckrodt sought to invalidate BioVie’s patent (U.S. Pat. No. 9,655,945, “Treatment of Ascites”) (the “’945 Patent”). In its decision, the Board determined that all claims of the ‘945 Patent were not patentable because they were either anticipated or obvious in light of prior art. The Board also denied BioVie’s Motion to Amend the claims on similar grounds. The result of the Board’s decision is that the ‘945 patent is no longer valid or enforceable. Acuitas Group Holdings, LLC was aware of this patent challenge when it purchased a majority ownership interest in the company in July 2018.

BioVie is evaluating the Board’s decision to determine if it will request a rehearing by the Board or appeal the Board’s decision to the U.S. Court of Appeals for the Federal Circuit. This ruling is unrelated to the Company’s Orphan drug designations for ascites and hepatorenal syndrome (“HRS”), which remain unchanged. An Orphan drug that is first-to-market typically receives 7 years of market exclusivity in the United States for the designated use(s). In addition, the ruling does not affect the Company’s rights in its pending patent application directed to proprietary liquid formulations of terlipressin for use in its planned Phase 2b/3 trial, subject to FDA clearance, which could eventually provide up to 20 years of patent coverage in each country in which the Company seeks patent protection, such as the United States, if a patent issues from a patent application according to the patent laws of each issuing country.

At September 30, 2019, no adjustments or accruals have been reflected in our financial statements related to this matter. (See Note 9 – Subsequent events.)

Royalty Agreements

Pursuant to the Agreement and Plan of Merger entered into on April 11, 2016 between our predecessor entities, LAT Pharma LLC and NanoAntibiotics, Inc., BioVie is obligated to pay a low single digit royalty on net sales of BIV201 (continuous infusion terlipressin) to be shared among LAT Pharma Members, PharmaIn Corporation, and The Barrett Edge, Inc.

The Company and PharmaIN Corporation, LAT Pharma’s former partner focused on the development of new modified drug candidates in the same therapeutic field but not including BIV201, had agreed to pay royalties equal to less than 1% of future net sales of each company's ascites drug development programs, or if such program is licensed to a third party, less than 5% of each company's net license revenues. On December 24, 2018, the Company returned its partial ownership rights to the PharmaIN modified terlipressin development program and simultaneously paid the remaining balance due on a related debt. PharmaIN, Corp. rights to our program remain unchanged.

Pursuant to the Technology Transfer Agreement entered into on July 25, 2016 between BioVie and the University of Padova (Italy), BioVie is obligated to pay a low single digit royalty on net sales of all terlipressin products covered by US patent no. 9,655,645 and any future foreign issuances capped at a maximum of $200,000 per year.

-15-

Table of Contents

BIOVIE INC.

Notes to Condensed Financial Statements

For the Three Months Ended September 30, 2019 and 2018

(unaudited)

9.	Subsequent Events

On October 1, 2019, the Company issued stock options to purchase 100,000 shares of common stock to the Chief Financial Officer as part of her compensation. The stock options were issued and are exercisable at an exercise price of $0.07 at any time from date of issuance and expire in 5 years from the date of issuance.

On October 13, 2019, the Company issued stock options to purchase 100,000 shares of common stock as part of their annual board of director compensation. The stock options were issued and are exercisable at $0.06 at any time from date of issuance and expire in 5 years from the date of issuance.

On November 7, 2019, the Company filed a certificate with the Nevada Secretary of State to terminate the effectiveness of Amendment of Article 3 to effect reverse split of the Corporation’s common stock in the ratio of 1:125.

On November 13, 2019, the Patent Trial and Appeal Board of the United States Patent and Trademark Office (the “Board”) issued a written decision in the inter partes review (“IPR”) action that was brought by Mallinckrodt Pharmaceuticals Ireland Limited (“Mallinckrodt”) against BioVie Inc. (“BioVie” or “Company”). In that action, Mallinckrodt sought to invalidate BioVie’s patent (U.S. Pat. No. 9,655,945, “Treatment of Ascites”) (the “’945 Patent”). In its decision, the Board determined that all claims of the ‘945 Patent were not patentable because they were either anticipated or obvious in light of prior art. The Board also denied BioVie’s Motion to Amend the claims on similar grounds. The result of the Board’s decision is that the ‘945 patent is no longer valid or enforceable. Acuitas Group Holdings, LLC was aware of this patent challenge when it purchased a majority ownership interest in the company in July 2018.

-16-

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

This report contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, and Section 27A of the Securities Act of 1933. Any statements contained in this report that are not statements of historical fact may be forward-looking statements. When we use the words “intends,” “estimates,” “predicts,” “potential,” “continues,” “anticipates,” “plans,” “expects,” “believes,” “should,” “could,” “may,” “will” or the negative of these terms or other comparable terminology, we are identifying forward-looking statements. Forward-looking statements involve risks and uncertainties, which may cause our actual results, performance or achievements to be materially different from those expressed or implied by forward-looking statements. These factors include our; research and development activities, distributor channel; compliance with regulatory impositions; and our capital needs. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

The following discussion of the Company’s financial condition and the results of operations should be read in conjunction with the Financial Statements and Notes thereto appearing elsewhere in this document.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements. In order to comply with the terms of the safe harbor, the Company notes that in addition to the description of historical facts contained herein, this report contains certain forward-looking statements that involve risks and uncertainties as detailed herein and from time to time in the Company’s other filings with the Securities and Exchange Commission and elsewhere. Such statements are based on management’s current expectations and are subject to a number of factors and uncertainties, which could cause actual results to differ materially from those, described in the forward-looking statements. These factors include, among others: (a) the Company’s fluctuations in sales, expenses and operating results; (b) risks associated with international operations; (c) regulatory, competitive and contractual risks; (d) product development risks; (e) the ability to achieve strategic initiatives, including but not limited to the ability to achieve sales growth across the business segments through a combination of enhanced sales force, new products, and customer service; and (f) pending litigation.

-17-

Table of Contents

Management’s Discussion

BioVie is a clinical-stage company pursuing the discovery, development, and commercialization of innovative drug therapies targeting life-threatening complications of liver cirrhosis. Our initial disease target is ascites, a serious medical condition affecting about 100,000 Americans and many times more worldwide. Our therapeutic drug candidate BIV201 is based on a drug that is approved in about 40 countries to treat related complications of liver cirrhosis (part of the same disease pathway as ascites), but not yet available in the US. The active agent in BIV201, terlipressin, is a potent vasoconstrictor which is in use for various medical conditions around the world. The goal is for BIV201 to interrupt the ascites disease pathway, thereby halting the cycle of accelerating fluid generation in ascites patients.

Comparison of the three months ended September 30, 2019 to the three months ended September 30, 2018

Net Loss

The net loss for the three months ended September 30, 2019 was $3.8 million as compared to $440,000 for the three months ended September 30, 2018. The increase in net loss of $3.4 million was due to an increase in interest expense of approximately $3.5 million and increased operating expenses of $214,000 offset by the increase in the change in value of derivative liabilities of $363,000. The increase in interest expense was attributed to the issuance of a 10% OID Convertible Delayed Draw Debenture (“Debenture”), which is convertible into shares of common stock. The interest expense for the three months ended September 30, 2019 was comprised of approximately $2.5 million related to the embedded derivative on the Debenture and interest expense of approximately $837,000 related to derivative liability – warrants.

Total operating expenses for the three months ended September 30, 2019 were approximately $706,000 compared to $491,000 for the three months ended September 30, 2018. The net increase of approximately $215,000 was primarily due to activities related to the Phase 2a clinical trials wrap up and preparation of the protocols for the Phase 2b/3 trials during the three months ended September 30, 2019 and an increase in selling, general and administrative expenses.

Research and Development Expenses

Research and development expenses were approximately $342,000 for the three months ended September 30, 2019, an increase of $147,000, from $195,000 for the three months ended September 30, 2018. The increase was primarily attributed to the wrapping up of the phase 2a clinical trials and readying for the next phase of trials including the preparing the protocols and manufacturing of the prefilled syringe which will be used in the next phase of trials.

Selling, General and Administrative Expenses

Selling, general and administrative expenses were approximately $307,000 for the three months ended September 30, 2019, a net increase of approximately $68,000, from $240,000 for the three months ended September 30, 2018. The net increase was primarily attributed to the increased payroll of approximately $30,000 due the hiring of a half time chief financial officer that joined in October 2018, an increase in the insurance premiums of approximately $15,000 for increased coverage and other expenses of approximately $13,000 related to activities of the Company’s capital raise and up listing to the Nasdaq.

Capital Resources and Liquidity

At September 30, 2019 the Company had approximately $249,000 in cash and cash equivalents and had completed its Phase 2a clinical trial of the BIV201 therapy. On September 24, 2019, the Company entered into a Securities Purchase Agreement with its controlling stockholder regarding bridge financing (the “Bridge Financing”) in the form of up to $2.0 million in convertible debt and warrants, of which $500,000 has been drawn to date. Amounts borrowed under the Bridge Financing must be repaid with the proceeds of our potential public offering of equity securities referred to below. The availability of additional draws under the Bridge Financing is under discussion with Acuitas in light of delays in the timing of the potential public offering. As further discussed below, the Company is pursuing various options to raise further financing to continue the testing and development of its product. If the Company is not successful in raising additional funds it may reduce its monthly spend and potentially delay the implementation of the larger scale Phase 2b Clinical trial until sufficient funding is secured.

-18-

Table of Contents

As of September 30, 2019, the Company had an accumulated deficit of $28.2 million and as a development stage enterprise, the Company expects substantial losses in future periods. The accompanying interim financial statements were prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company’s future operations are dependent on the success of the Company’s ongoing development and commercialization effort, as well as continuing to secure additional financing.

We cannot assure you that our drug candidate will be developed, work, or receive regulatory approval; that we will ever earn revenues sufficient to support our operations or that we will ever be profitable. Furthermore, since we have no committed source of sufficient financing, we cannot assure you that we will be able to raise money as and when we need it to continue our operations. If we cannot raise funds as and when we need them, we may be required to severely curtail, or even to cease, our operations.

Additionally, in April 2019, to facilitate our planned up listing to the NASDAQ Stock Market and related potential future issuances and sales of our equity securities for ordinary corporate finance and general corporate purposes and as recommended by our Board of Directors (“Board”), our stockholders approved an amendment to our Articles of Incorporation to effect a reverse split of our outstanding Class A common stock in the range of 50:1 to 200:1, as determined by our Board. Following that approval, we filed a Registration Statement on Form S-1 (Registration No. 333-231136) (the “S-1 Registration Statement”) pursuant to which we anticipate completing an offering of our equity securities with proceeds sufficient to enable the launch and completion of the BIV201 Phase 2b study and fund our internal operations for at least the next twelve months. There can be no assurance, however, that we will successfully complete an offering on the terms contemplated by the S-1 Registration Statement or on any commercially reasonable terms.

Management intends to attempt to secure additional required funding primarily through additional equity or debt financings. We may also seek to secure required funding through sales or out-licensing of intellectual property assets, seeking partnerships with other pharmaceutical companies or third parties to co-develop and fund research and development efforts, or similar transactions. However, there can be no assurance that we will be able to obtain required funding. If we are unsuccessful in securing funding from any of these sources, we will defer, reduce or eliminate certain planned expenditures in our research protocols. If we do not have sufficient funds to continue operations, we could be required to seek bankruptcy protection or other alternatives that could result in our stockholders losing some or all of their investment in us.

These circumstances raise substantial doubt on our ability to continue as a going concern. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might result from this uncertainty.

Off-Balance Sheet Arrangements

The Company has no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect or change on the Company’s financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors. The term “off-balance sheet arrangement” generally means any transaction, agreement or other contractual arrangement to which an entity unconsolidated with the Company is a party, under which the Company has (i) any obligation arising under a guarantee contract, derivative instrument or variable interest; or (ii) a retained or contingent interest in assets transferred to such entity or similar arrangement that serves as credit, liquidity or market risk support for such assets.

-19-

Table of Contents

Critical Accounting Policies and Estimates

For the three-month period ended September 30, 2019, there were no significant changes to the Company’s critical accounting policies as identified in the Annual Report Form 10-K for the fiscal year ended June 30, 2019.

New Accounting Pronouncements

The Company considered the applicability and impact of recent accounting pronouncements and determined those to be either not applicable or expected to have minimal impact on our balance sheets or statement of operations.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Not applicable

Item 4. Controls and Procedures

We maintain “disclosure controls and procedures.” Such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act that are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Office and Chief Financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Our disclosure controls and procedures have been designed to meet reasonable assurance standards. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgement in evaluating the cost-benefit relationship of possible disclosure and procedures. The design of and disclosure controls and procedures also are based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

Based on their evaluation as of the end of the period covered by this Quarterly Report on Form 10-Q our Chief Executive Officer and Chief Financial Officer have concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rule 13a-15f and 15d-15(f) under the Exchange Act), that occurred during the quarter ended September 30, 2019 that have materially affected or are reasonably likely to materially affect, our internal control over financial reporting.

-20-

Table of Contents

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

To our knowledge, neither the Company nor any of our officers or directors is a party to any material legal proceeding or litigation and such persons know of no material legal proceeding or contemplated or threatened litigation. There are no judgments against us or our officers or directors. None of our officers or directors has been convicted of a felony or misdemeanor relating to securities or performance in corporate office.

On April 30, 2018, we received notice that Mallinckrodt had petitioned the U.S. Patent and Trademark Office (“USPTO”) to institute an Inter Partes Review of our U.S. Patent No. 9,655,945 titled “Treatment of Ascites” (the “’945 patent”). Inter Partes Review is a trial proceeding conducted with the USPTO Patent Trial and Appeal Board (PTAB) to review the patentability of one or more claims of a patent. Such review is limited to grounds of novelty and obviousness on the basis of prior art consisting of patents and printed publications. For further information regarding these proceedings, please see footnote 5 in the accompanying interim financial statements.

Item 2. Unregistered sales of equity securities

All sales of unregistered securities during the three months ended September 30, 2019 were previously disclosed in a Current report on Form 8-K.

Item 3. Defaults Upon Senior Securities

None

Item 4. Mine Safety Disclosures

None

Item 5. Other Information

None

-21-

Table of Contents

Item 6. Exhibits

(a) Exhibit index

Exhibit

31.1*		Certification of Chief Executive Officer (Principal Executive Officer) required by Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended.
31.2*		Certification of Chief Financial Officer (Principal Financial Officer) required by Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended.
32.1**		Certifications of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2**		Certification of Chief Financial Officer (Principal Financial Officer) pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS		XBRL Instance Document

101.SCH		XBRL Taxonomy Extension Schema Document

101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document

101.LAB		XBRL Taxonomy Extension Label Linkbase Document

101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

101.DEF		XBRL Taxonomy Extension Definition Linkbase Document

*	Filed herewith.

**	Furnished herewith. This certification is being furnished solely to accompany this report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filings of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

-22-

Table of Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BioVie Inc.,


Signature	Titles	Date

/s/Terren Peizer ________________ Terren Peizer	Chairman and Chief Executive Officer (Principal Executive Officer)	November 19, 2019
/s/Joanne Wendy Kim _________________ Joanne Wendy Kim	Chief Financial Officer (Principal Financial and Accounting Officer)	November 19, 2019

-23-

EX-31.1 2 bivi-20190930_10qex31z1.htm EXHIBIT 31.1

Exhibit 31.1

CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES OXLEY ACT OF 2002

AND RULE 13-A14 OF THE EXCHANGE ACT OF 1934

CERTIFICATION

I, Terren Peizer, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of BioVie Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a – 15(f) and 15d – 15(f)) for the registrant and have:

	a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of the annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.		The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 19, 2019

								/s/ Terren S. Peizer
								Terren S. Peizer Chief Executive Officer (Principal Executive Officer)

EX-31.2 3 bivi-20190930_10qex31z2.htm EXHIBIT 31.2

Exhibit 31.2

CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES OXLEY ACT OF 2002

AND RULE 13-A14 OF THE EXCHANGE ACT OF 1934

CERTIFICATION

I, Joanne Wendy Kim, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of BioVie Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a – 15(f) and 15d – 15(f)) for the registrant and have:

	a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of the annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.		The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 19, 2019

/s/ Joanne Wendy Kim

Joanne Wendy Kim

Chief Financial Officer
(Principal Financial and Accounting Officer)

EX-32.1 4 bivi-20190930_10qex32z1.htm EXHIBIT 32.1

Exhibit 32.1

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S. C. SECTION 1350 AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of BioVie Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2019, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Terren Peizer, Chief Executive Officer and Chairman of the Board of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002, that, to my knowledge:

(1)	The Report fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934; and

(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 19, 2019

								/s/ Terren S. Peizer
								Terren S. Peizer Chief Executive Officer (Principal Executive Officer)

EX-32.2 5 bivi-20190930_10qex32z2.htm EXHIBIT 32.2

Exhibit 32.2

CERTIFICATION OF THE CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S. C. SECTION 1350 AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of BioVie Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2019, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Joanne Wendy Kim, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002, that, to my knowledge:

(1)	The Report fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934; and

(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 19, 2019

/s/ Joanne Wendy Kim

Joanne Wendy Kim

Chief Financial Officer
(Principal Financial and Accounting Officer)

EX-101.INS 6 bivi-20190930.xml XBRL INSTANCE FILE 0001580149 2019-11-18 0001580149 2019-07-01 2019-09-30 0001580149 2019-09-30 0001580149 us-gaap:CommonStockMember 2019-06-30 0001580149 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001580149 us-gaap:RetainedEarningsMember 2019-06-30 0001580149 us-gaap:StockOptionMember 2019-06-30 0001580149 bivi:StockOptionOneMember 2019-07-01 2019-09-30 0001580149 bivi:StockOptionOneMember 2019-09-30 0001580149 bivi:StockOptionTwoMember 2019-07-01 2019-09-30 0001580149 bivi:StockOptionTwoMember 2019-09-30 0001580149 bivi:StockOptionThreeMember 2019-07-01 2019-09-30 0001580149 bivi:StockOptionThreeMember 2019-09-30 0001580149 bivi:StockOptionFourMember 2019-07-01 2019-09-30 0001580149 bivi:StockOptionFourMember 2019-09-30 0001580149 bivi:StockOptionFiveMember 2019-07-01 2019-09-30 0001580149 bivi:StockOptionFiveMember 2019-09-30 0001580149 bivi:StockOptionSixMember 2019-07-01 2019-09-30 0001580149 bivi:StockOptionSixMember 2019-09-30 0001580149 bivi:StockOptionSevenMember 2019-07-01 2019-09-30 0001580149 bivi:StockOptionSevenMember 2019-09-30 0001580149 us-gaap:PreferredStockMember 2019-09-30 0001580149 us-gaap:PreferredStockMember 2019-06-30 0001580149 us-gaap:CommonStockMember 2019-09-30 0001580149 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001580149 us-gaap:RetainedEarningsMember 2019-09-30 0001580149 us-gaap:WarrantMember 2019-07-01 2019-09-30 0001580149 us-gaap:StockOptionMember 2019-07-01 2019-09-30 0001580149 us-gaap:StockOptionMember 2019-09-30 0001580149 us-gaap:PreferredStockMember 2018-07-01 2018-09-30 0001580149 us-gaap:CommonStockMember 2018-07-01 2018-09-30 0001580149 us-gaap:AdditionalPaidInCapitalMember 2018-07-01 2018-09-30 0001580149 us-gaap:RetainedEarningsMember 2018-07-01 2018-09-30 0001580149 2018-07-01 2018-09-30 0001580149 bivi:StockOptionEightMember 2019-09-30 0001580149 bivi:StockOptionEightMember 2019-07-01 2019-09-30 0001580149 bivi:StockOptionNineMember 2019-09-30 0001580149 bivi:StockOptionNineMember 2019-07-01 2019-09-30 0001580149 us-gaap:WarrantMember 2019-09-30 0001580149 us-gaap:WarrantMember 2019-06-30 0001580149 2019-06-30 0001580149 us-gaap:PreferredStockMember 2018-09-30 0001580149 us-gaap:CommonStockMember 2018-09-30 0001580149 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0001580149 us-gaap:RetainedEarningsMember 2018-09-30 0001580149 2018-09-30 0001580149 bivi:StockOptionTenMember 2019-09-30 0001580149 bivi:StockOptionTenMember 2019-07-01 2019-09-30 0001580149 2018-06-30 0001580149 us-gaap:PreferredStockMember 2019-07-01 2019-09-30 0001580149 us-gaap:PreferredStockMember 2018-06-30 0001580149 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0001580149 us-gaap:CommonStockMember 2018-06-30 0001580149 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0001580149 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0001580149 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0001580149 us-gaap:RetainedEarningsMember 2018-06-30 0001580149 us-gaap:StockOptionMember 2018-07-01 2018-09-30 0001580149 us-gaap:WarrantMember 2018-07-01 2018-09-30 0001580149 bivi:DerivativeLiabilityWarrantsMember 2019-09-30 0001580149 bivi:DerivativeLiabilityConversionOptionOnConvertibleDebentureMember 2019-09-30 0001580149 bivi:DerivativeLiabilityWarrantsMember us-gaap:FairValueInputsLevel3Member 2019-09-30 0001580149 bivi:DerivativeLiabilityConversionOptionOnConvertibleDebentureMember us-gaap:FairValueInputsLevel3Member 2019-09-30 0001580149 us-gaap:FairValueInputsLevel3Member 2019-09-30 0001580149 bivi:DerivativeLiabilityWarrantsMember us-gaap:FairValueInputsLevel3Member 2019-07-01 2019-09-30 0001580149 bivi:DerivativeLiabilityConversionOptionOnConvertibleDebentureMember us-gaap:FairValueInputsLevel3Member 2019-07-01 2019-09-30 0001580149 bivi:DerivativeLiabilityWarrantsMember us-gaap:FairValueInputsLevel3Member 2019-06-30 0001580149 bivi:DerivativeLiabilityConversionOptionOnConvertibleDebentureMember us-gaap:FairValueInputsLevel3Member 2019-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

765388

674073

2608358

2574387

684060

443480

11328986

443480

19396936

9342249

-8720628

2130907

2608358

2574387

10000000

800000000

647930147

507305147

-590914

-441882

500000

2531700

64793

50730

0.001

647930147

507305147

240580

-62767

-90914

2089818

249009

339923

2135619

45800

0.0001

-28182357

-7262072

1497259

1554603

345711

1842970

1900314

57344

341501

194521

307373

239562

706218

491427

-706218

-491427

3477615

272

428

-0.04

0.00

516577125

309279009

7250000

700000

1300000

3100000

100000

500000

200000

550000

7250000

100000

200000

500000

0.10

0.03

0.05

0.06

0.07

0.10

0.20

0.21

0.10

0.22

0.23

0.25

500000

647930147 BIOVIE INC. 0001580149 10-Q 2019-09-30 false --06-30 Yes Non-accelerated Filer Q1 2020

11328986

443480

-3821227

-439871

-3821227

17099058 48659

507305147

647930147

315053673

98503199

-8720628

50730

9342249

-7262072

64793

19396936

-28182357

2130907

31505

9251025

-5257655

4024876

111199

9850

4870474

-4769126

-17099058 48659 -48659 -17099058

179083216

171833216

7250000

221591548

5150000

216441548

1497259

1554603

796511

739167

2293770

700000

1300000

3100000

100000

500000

200000

550000

7250000

100000

200000

500000

P4Y3M18D

P4Y4M24D

P6Y4M24D

P4Y0M0D

P3Y3M18D

P3Y0M0D

P2Y7M6D

P5Y2M12D

P2Y6M0D

P2Y10M24D

P2Y1M6D

15583216

0.36

P5Y3M18D

156250000

0.03

P5Y3M18D

P5Y

3040000

3200000 98 1150037 1150135 224 -224 48659

411

3200000 3200000 3200000 2133332 -3200000 21333 -21333 -2133332 213333200

3412

0.10

-20920285

-488530

3115009 -51556 true false

-508300

975361 2241913

The table below shows the number of outstanding stock options and warrants as of September 30, 2019 and 2018:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">September 30, 2019</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">September 30, 2018</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of Shares</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of Shares</td></tr> <tr style="vertical-align: bottom"> <td style="width: 56%; text-align: left; padding-left: 5.4pt">Stock Options</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">7,250,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">5,150,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; padding-left: 5.4pt">Warrants</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">171,833,216</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">216,441,548</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 5.4pt">Total</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">179,083,216</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">221,591,548</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table>

171833216

0.04

87480

6622903

716653

5906250

516379

334150

-182229

87480

172032

229377

178342

NV 001-39015 Yes 1534 2533668 8109724

51400

362586

7530308 3477204

140625000

10068750

14063

10054687

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="width: 2%; font: 10pt Times New Roman, Times, Serif">5.</td> <td style="width: 98%; font: 10pt Times New Roman, Times, Serif">Related Party Transactions</td></tr> </table>   Equity Transactions with Acuitas   On July 3, 2018, we entered into a Securities Purchase Agreement (the “Purchase Agreement”) with Acuitas Group Holding, LLC (“Acuitas”) and certain other purchasers identified in the Purchase Agreement (together with Acuitas, the “Purchasers”) pursuant to which (i) the Purchasers agreed to purchase an aggregate of 2,133,332 shares of the our Series A Convertible Preferred Stock (the “Preferred Stock”) at a price per share of $1.50 per share of Preferred Stock (the “Initial Sale”) and (ii) we agreed to issue warrants (the “Warrants”) to purchase 213,333,200 shares of common stock, each subject to the terms and conditions set forth in the Purchase Agreement, for an aggregate consideration of $3.2 million. We received $160,000 of the $3.2 million in April and May 2018 as prepaid equity. Acuitas also received an additional 833,333 Warrants in connection with the payoff of a note issued by us in favor of Acuitas. The Initial Sale and issuance of the Warrants occurred on July 3, 2018. In addition, Acuitas had the option to purchase up to an additional 200,000,000 shares of common stock at a price per share of $0.015, and warrants on the same terms as the Warrants, within two weeks following the one year anniversary of the closing of the Initial Sale (the “Subsequent Sale”) in the event that we did not obtain $3,000,000 of funding through various non-dilutive grants prior to the one year anniversary of the closing of the Initial Sale, less any federal or FDA grant funding received by the Company. Acuitas is controlled by our Chairman and Chief Executive Officer, Terren Peizer and the Purchasers included Jonathan Adams, James Lang, Cuong Do and Michael Sherman, who are members of our Board.   The Purchase Agreement contained customary representations and warranties. In connection with the disclosure schedule associated with the representations and warranties, we also disclosed customary information, including the following: (i) the existence of the Mallinckrodt petition before the U.S. Patent Trial and Appeal Board, (ii) our capitalization, (iii) our obligation to pay a low single digit royalty on the net sales of BIV201 (continuous infusion terlipressin) to be shared among LAT Pharma LLC members, PharmaIN Corporation and The Barrett Edge, Inc. pursuant to the Agreement and Plan of Merger, dated April 11, 2016, by and between LAT Pharma LLC and us, (iv) our obligation to pay a low single digit royalty on net sales of all terlipressin products covered by specified patents up to a maximum of $200,000 per year pursuant to the Technology Transfer Agreement, dated July 25, 2016, by and between us and the University of Padova (Italy), and (v) certain recent issuances of common stock by us.   Each share of Preferred Stock automatically converted into 100 shares of common stock upon the filing with the Secretary of State of the State of Nevada of a Certificate of Amendment to our Articles of Incorporation (the “Amendment”) on August 13, 2018 that increased the number of authorized shares of common stock to 800,000,000. The Amendment was approved by the written consent of the holders of more than a majority of our issued and outstanding common stock on July 3, 2018 and was filed with the Secretary of State of the State of Nevada 20 calendar days following the distribution of our Definitive Information Statement on Schedule 14 that was filed with the SEC on July 13, 2018.   Pursuant to a letter agreement dated June 24, 2019, Acuitas agreed to modify its existing rights under the Purchase Agreement so that:   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="width: 20px; padding: 0; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">•</td> <td style="width: 7px; font: 10pt Times New Roman, Times, Serif; padding: 0"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify">Acuitas agreed to immediately exchange its existing 200,833,333 Warrants for common stock such that it will have effectively exercised its Warrants in full pursuant to a cashless exercise thereof at an assumed current market price of $0.36 per share and, as a result received an aggregate of 95% of the shares covered thereby, or 190,761,666 shares of common stock;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding: 0"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="width: 20px; padding: 0; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">•</td> <td style="width: 7px; font: 10pt Times New Roman, Times, Serif; padding: 0"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify">Acuitas agreed to (i) waive its rights to a 50% adjustment of the purchase price of the Preferred Stock in the Initial Sale, the exercise price of the Warrants and the price per share in the Subsequent Sale in the event of certain reductions in the useful life of our current intellectual property rights, and (ii) effectively exercise its rights to purchase securities in a Subsequent Sale pursuant to a “cashless purchase” at an assumed current market price of approximately $0.09 per share, conditioned in each case on the listing of our common stock on Nasdaq or the raising of $2.0 million in additional funds in the form of another securities offering, in either case not later than November 30, 2019, which will result Acuitas having irrevocably waived its rights to an adjustment in the purchase price of the Preferred Stock in the Initial Sale and the exercise price of the Warrants and the purchase price of per share in the Subsequent Sale upon the issuance by us of an aggregate of 167,494,750 shares of common stock (the “Subsequent Sale Shares”) to Acuitas, which is expected to occur concurrently with the closing of our potential public offering and listing on Nasdaq;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding: 0"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="width: 20px; padding: 0 0 0 -30pt; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">•</td> <td style="width: 7px; font: 10pt Times New Roman, Times, Serif; padding: 0"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: justify">Acuitas shall in exchange for the foregoing agreements and waivers have the option to purchase additional shares of common stock and warrants to purchase one share of common stock for each share of common stock purchased during the period from September 1, 2019 to November 30, 2019 at the then-effective purchase price of the Preferred Stock in the Initial Sale (the “Funding Option”), provided that any shares issued pursuant to any exercise of the Funding Option will reduce share-for-share the amount of shares issued pursuant to the deemed exercise of its rights to purchase securities in a Subsequent Sale mentioned above.</td></tr> </table>   Convertible Debenture Transaction with Acuitas   On September 24, 2019, the Company entered into a Securities Purchase Agreement (the “2019 Purchase Agreement”) with Acuitas pursuant to which (i) Acuitas agreed to purchase a 10% OID Convertible Delayed Draw Debenture (the “Debenture”) due September 24, 2020 for an aggregate commitment amount of up to $2.0 million, and (ii) the Company issued 140,625,000 shares (the “Commitment Shares”) of the Company’s common stock and warrants (the “Commitment Warrants”) to purchase an equal number of shares, each subject to the terms and conditions set forth in the 2019 Purchase Agreement. The Debenture accrues additional principal at the rate of 6% per annum and interest at the rate of 10% per annum, is convertible into shares of common stock at $0.032 per share prior to the completion of the company’s planned public offering of units (the “Public Offering”) or, subsequent to the closing of the Public Offering, the lower of $0.032 or 80% of the offering price per unit to the public in the Public Offering and are mandatorily redeemable upon such closing at 100% of the accrued principal amount and unpaid interest to the date of redemption. The Commitment Warrants are five-year warrants, exercisable upon the earlier of the effectiveness of the Company’s currently pending reverse stock split or December 1, 2019, at an amount equal to the lower of $0.032 or 80% of the offering price per unit to the public in the Public Offering. Upon entering into the 2019 Purchase Agreement, the Company drew an initial $500,000 under the Debenture and in accordance with the 2019 Purchase Agreement, Acuitas received an additional 15,625,000 warrants (the “Bridge Warrants”) having the same terms as the Commitment Warrants. Any future draws under the Debenture, which may be made from and after October 15, 2019, November 15, 2019 and December 15, 2019 in equal tranches of $500,000 each, will entitle Acuitas to receive additional Bridge Warrants in equal amount upon such funding. In addition, the 2019 Purchase Agreement provides that, should the underwriters in the Public Offering exercise their option to purchase additional securities during the 45 days following closing and the issuance of such securities would result in Acuitas' beneficial ownership (on a fully diluted basis) of shares of common stock being below 60%, Acuitas shall be issued a number of additional shares of common stock and warrants having the same terms as the Commitment Warrants to result in its beneficial ownership (on a fully diluted basis) of shares of common stock equaling 60%.   The issuance of 140,625,000 shares of the Company’s commons stock and warrants to purchase an equal amount number of shares, to its controlling stockholder for the Bridge Financing was accounted for as a deemed dividend due to its related party nature and $17.1 million representing the debt discount, net of the outstanding draw amount; was recorded in accumulated deficit for the three months ended September 30, 2019, accordingly. (See accompanied Condensed Statements of Changes in Stockholders’ (Deficit) Equity). A debt discount of $500,000 against the debenture was recorded which will be amortized over the term of the debenture using the effective interest method. The Company recognized amortization of this discount in the amount of $1,534 for the three-month period ended September 30, 2019.   Pursuant to the 2019 Purchase Agreement, Acuitas has agreed to further modify its existing rights under the Purchase Agreement dated July 3, 2018 with the Company so that Acuitas’ previous agreement in June 2019 to waive its rights to a 50% adjustment of the purchase price of the Preferred Stock in the July 2018 transaction, the exercise price of the warrants in such transaction and the price per share in a Subsequent Sale in the event of certain reductions in the useful life of our current intellectual property rights, and effectively exercise its rights to purchase securities in a Subsequent Sale pursuant to a “cashless purchase” at an assumed current market price of approximately $0.09 per share, conditioned in each case on the listing of the Company’s common stock on Nasdaq or the raising of $2.0 million in additional funds in the form of another securities offering, in either case not later than November 30, 2019, such that Acuitas will have irrevocably waived its rights to an adjustment in the purchase price of the Preferred Stock in the Initial Sale and the exercise price of the Warrants and the purchase price of per share in the Subsequent Sale upon the issuance by us of an aggregate of 334,989,500 shares of common stock and 334,989,500 warrants having the same terms as the Commitment Warrants to Acuitas, upon the closing of the Public Offering.   Pursuant to an amendment to the 2019 Purchase Agreement dated October 9, 2019, Acuitas agreed to modify its existing rights under the 2019 Purchase Agreement so that:   <table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="width: 24px; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 24px; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">•</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Commitment Warrants (and related warrants issued upon the first draw under the Debenture) were replaced with warrants having similar terms, but which are automatically exercised upon the closing of the offering at an exercise price equal to the par value of the common stock;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="width: 24px; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 24px; font: 10pt Times New Roman, Times, Serif; padding-left: -10pt; text-align: center; vertical-align: top">•</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Acuitas' existing rights under the Purchase Agreement dated July 3, 2018 with the Company were further amended so that the number of Subsequent Sale Shares would be multiplied by four (in lieu of the changes to the Purchase Agreement originally provided for in the 2019 Purchase Agreement); and</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="width: 24px; font: 10pt Times New Roman, Times, Serif"> </td> <td style="width: 24px; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top">•</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The provisions of the 2019 Purchase Agreement providing that, should the underwriters in the offering exercise their option to purchase additional securities during the 45 days following closing and the issuance of such securities would result in Acuitas’ beneficial ownership (on a fully diluted basis) of shares of common stock being below 60%, Acuitas will be issued a number of additional shares of common stock and warrants having the same terms as the Commitment Warrants to result in its beneficial ownership (on a fully diluted basis) of shares of common stock equaling 60% have been modified such that, upon the exercise of such option by the underwriters, the Company will issue to Acuitas a number of securities that will result in Acuitas’ fully diluted beneficial ownership after the exercise of such option being the same as prior thereto. </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif"> <tr style="font: 10pt Times New Roman, Times, Serif"> <td style="width: 2%; font: 10pt Times New Roman, Times, Serif">7.</td> <td style="width: 98%; font: 10pt Times New Roman, Times, Serif">Equity Transactions</td></tr> </table>   Stock Options   The following table summarizes the activity relating to the Company’s stock options for the three months ended September 30, 2019:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted-Average Exercise Price</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted Remaining Average Contractual Term</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Aggregate Intrinsic Value</td></tr> <tr style="vertical-align: bottom"> <td style="width: 40%; padding-left: 5.4pt">Outstanding at June 30, 2019</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">7,250,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">0.10</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">5.2</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">87,480</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 5.4pt">Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Options Exercised or Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt">Outstanding at September 30, 2019</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">7,250,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.10</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">4.8</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">87,480</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt">Exercisable at  September 30, 2019</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">7,250,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.10</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">4.8</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">87,480</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   The fair value of each option grant on the date of grant is estimated using the Black-Scholes option. There were no options granted during the three months ended September 30, 2019. The pricing model reflected the following weighted-average assumptions for the three months ended September 30, 2018:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September 30 2019</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September 30 2018</td></tr> <tr style="vertical-align: bottom"> <td style="width: 56%; text-align: left; padding-left: 5.4pt">Expected life of options (In years)</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">—  </td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">9.5</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-left: 5.4pt">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">63.09</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-left: 5.4pt">Risk free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.00</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-left: 5.4pt">Dividend Yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td></tr> </table>   Expected volatility is based on the historical volatilities of three comparable companies of the daily closing price of their respective common stock and the expected life of options is based on historical data with respect to employee exercise periods. The Company accounts for forfeitures as they are incurred.   The Company recorded stock-based compensation expense of $0 and $3,412 for the three- month period ended September 30, 2019 and 2018, respectively.   The following is a summary of stock options outstanding and exercisable by exercise price as of September 30, 2019:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Exercise Price</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Outstanding</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Weighted Average Contract Life</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Exercisable</td></tr> <tr style="vertical-align: bottom"> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">0.03</td><td style="width: 1%; text-align: left"> </td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 19%; text-align: right">700,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 19%; text-align: right">4.3</td><td style="width: 1%; text-align: left"> </td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 19%; text-align: right">700,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">$</td><td style="text-align: right">0.05</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,300,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.4</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,300,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">$</td><td style="text-align: right">0.06</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,100,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6.4</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,100,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">$</td><td style="text-align: right">0.07</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.0</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">$</td><td style="text-align: right">0.10</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">500,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">500,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">$</td><td style="text-align: right">0.20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">200,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.0</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">200,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">$</td><td style="text-align: right">0.21</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">550,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">550,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">$</td><td style="text-align: right">0.22</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">$</td><td style="text-align: right">0.23</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">200,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.9</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">200,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">$</td><td style="text-align: right">0.25</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">500,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">2.1</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">500,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="text-align: right">Total</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">7,250,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">7,250,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   Stock Warrants   The following table summarizes the warrants activity during the three months ended September 30, 2019:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of Shares</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted Average Exercise Price</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted Average Remaining Life (Years)</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Aggregate Intrinsic Value</td></tr> <tr style="vertical-align: bottom"> <td style="width: 40%; text-align: left; padding-left: 5.4pt">Outstanding and exercisable at June 30, 2019</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">15,583,216</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">0.36</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">5.6</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">716,653</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 5.4pt">Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">156,250,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.03</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.0</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">5,906,250</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; padding-left: 5.4pt">Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Outstanding and exercisable at September 30, 2019</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">171,833,216</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">0.04</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4.9</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">6,622,903</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>   Of the above warrants, 1,173,864 expire in fiscal year ending June 30, 2022, 556,818 expire in fiscal year ending June 30, 2023, and 170,102,534 expire in fiscal year ending June 30, 2025.

Basis of Presentation – Interim Financial Information   The accompanying unaudited interim financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United State of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities Exchange Commission for Interim Reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring accruals) that are, in the opinion of management, considered necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. The condensed balance sheet at June 30, 2019 was derived from audited annual financial statements but does not contain all the footnote disclosures from the annual financial statements. The accompanying financial statements and information included under the heading: “Management’s Discussion and Analysis of Financial Condition and Results of Operations” should be read in conjunction with our Company’s audited financial statements and related notes included in our Company’s Form 10-K for the year ended June 30, 2019 filed with the SEC on September 27, 2019.   For a summary of significant accounting policies, see the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2019 filed with the SEC on September 27, 2019.

Net Loss per Common Share   Basic net loss per common share is computed by dividing the net loss before deemed dividend by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding and potentially outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants, convertible preferred stock and convertible debentures. Due to the net loss for the period, such amounts were excluded from the diluted loss since their effect was considered anti-dilutive.   The table below shows the number of outstanding stock options and warrants as of September 30, 2019 and 2018:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">September 30, 2019</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">September 30, 2018</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of Shares</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of Shares</td></tr> <tr style="vertical-align: bottom"> <td style="width: 56%; text-align: left; padding-left: 5.4pt">Stock Options</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">7,250,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">5,150,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; padding-left: 5.4pt">Warrants</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">171,833,216</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">216,441,548</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 5.4pt">Total</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">179,083,216</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">221,591,548</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table>

Recent accounting pronouncements   The Company considers the applicability and impact of all Accounting Standard Updates (“ASU’s”). ASU’s not discussed below were assessed and determined to be either not applicable or expected to have minimal impact on our balance sheets or statement of operations.   In June 2018, the FASB issued ASU 2018-07, “Compensation – Stock Compensation (Topic 718): Improvements to Non-employee Share-Based Accounting”. This guidance aligns the accounting for share-based payment transactions with non-employees to accounting for share-based payment transactions with employees. Companies are required to record a cumulative-effect adjustment (net of tax) to retained earnings as of the beginning of the fiscal year of the adoption. Upon transition, non-employee awards are required to be measured at fair value as of the adoption date. This standard will be effective for fiscal years beginning December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. The Company has adopted this ASU as of July 1, 2019. There has been no impact on the financial statements.   In August 2018, the FASB issued ASU 2018-13, “Fair value measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement”. The new guidance modifies the disclosure requirements on fair value measurements. ASU 2018-13 is effective for fiscal years beginning after December 15, 2019. Early adoption is permitted. The Company does not expect ASU 2018-13 to have a significant impact to its condensed consolidated financial statements and related disclosures.

The following is a summary of the intangible assets as of September 30, 2019 and June 30, 2019:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September 30, 2019</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, 2019</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="3" style="text-align: center"> </td><td> </td> <td colspan="3" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 56%; text-align: left; padding-left: 5.4pt">Intellectual Property</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,293,770</td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,293,770</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Less Accumulated Amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(796,511</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(739,167</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Intellectual Property, Net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,497,259</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,554,603</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

Estimated future amortization expense is as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="width: 70%; text-align: center; padding-left: 5.4pt">Year ending June 30, 2020 (Remaining nine months)</td><td style="width: 10%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">172,032</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; padding-left: 5.4pt">2021</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">229,377</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; padding-left: 5.4pt">2022</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">229,377</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; padding-left: 5.4pt">2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">229,377</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; padding-left: 5.4pt">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">229,377</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; padding-left: 5.4pt">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">229,377</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center; padding-bottom: 1pt; padding-left: 5.4pt">Thereafter</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">178,342</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,497,259</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

At September 30, 2019, the estimated fair value of derivative liabilities measured on a recurring basis are as follows:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="15" style="font-weight: bold; text-align: center">Fair Value Measurements at</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="15" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September 30, 2019</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Level 1</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Level 2</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Level 3</td><td style="font-weight: bold"> </td> <td colspan="3" style="font-weight: bold; text-align: center">Total</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="3" style="text-align: center"> </td><td> </td> <td colspan="3" style="text-align: center"> </td><td> </td> <td colspan="3" style="text-align: center"> </td><td> </td> <td colspan="3" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 40%; text-align: left; padding-left: 5.4pt">Derivative liability – Warrants</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">—  </td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">—  </td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">8,109,724</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">8,109,724</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Derivative liability -Conversion option on convertible debenture</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,533,668</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,533,668</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">   Total derivatives</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—  </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">—  </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,643,392</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">10,643,392</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

The following table presents the activity for liabilities measured at fair value using unobservable inputs for the three months ended September 30, 2019:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Derivative liabilities - Warrants</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Derivative liability - Conversion Option on Convertible Debenture</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="3"> </td><td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 5.4pt">Beginning balance at July 1, 2019</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">—  </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 56%; text-align: left; padding-left: 5.4pt">Additions to level 3 liabilities</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">8,367,012</td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">2,638,966</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-left: 5.4pt">Change in in fair value of level 3 liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(257,288</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(105,298</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Transfer in and/or out of Level 3</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt">Balance at September 30, 2019</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,109,724</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,533,668</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

The following table summarizes the activity relating to the Company’s stock options for the three months ended September 30, 2019:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Options</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted-Average Exercise Price</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted Remaining Average Contractual Term</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Aggregate Intrinsic Value</td></tr> <tr style="vertical-align: bottom"> <td style="width: 40%; padding-left: 5.4pt">Outstanding at June 30, 2019</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">7,250,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">0.10</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">5.2</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">87,480</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 5.4pt">Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Options Exercised or Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt">Outstanding at September 30, 2019</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">7,250,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.10</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">4.8</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">87,480</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 2.5pt; padding-left: 5.4pt">Exercisable at  September 30, 2019</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">7,250,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">0.10</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">4.8</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">87,480</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   The pricing model reflected the following weighted-average assumptions for the three months ended September 30, 2018:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September 30 2019</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September 30 2018</td></tr> <tr style="vertical-align: bottom"> <td style="width: 56%; text-align: left; padding-left: 5.4pt">Expected life of options (In years)</td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">—  </td><td style="width: 1%; text-align: left"> </td><td style="width: 8%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right">9.5</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-left: 5.4pt">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">63.09</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-left: 5.4pt">Risk free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.00</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-left: 5.4pt">Dividend Yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0</td><td style="text-align: left">%</td></tr></table>

The following is a summary of stock options outstanding and exercisable by exercise price as of September 30, 2019:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Exercise Price</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Outstanding</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Weighted Average Contract Life</td><td style="padding-bottom: 1pt"> </td> <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid">Exercisable</td></tr> <tr style="vertical-align: bottom"> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">0.03</td><td style="width: 1%; text-align: left"> </td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 19%; text-align: right">700,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 19%; text-align: right">4.3</td><td style="width: 1%; text-align: left"> </td><td style="width: 5%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 19%; text-align: right">700,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">$</td><td style="text-align: right">0.05</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,300,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.4</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,300,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">$</td><td style="text-align: right">0.06</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,100,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6.4</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,100,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">$</td><td style="text-align: right">0.07</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.0</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">$</td><td style="text-align: right">0.10</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">500,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">500,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">$</td><td style="text-align: right">0.20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">200,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.0</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">200,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">$</td><td style="text-align: right">0.21</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">550,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">550,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">$</td><td style="text-align: right">0.22</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">$</td><td style="text-align: right">0.23</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">200,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.9</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">200,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">$</td><td style="text-align: right">0.25</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">500,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right">2.1</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">500,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="text-align: right">Total</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">7,250,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">7,250,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

The following table summarizes the warrants activity during the three months ended September 30, 2019:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Number of Shares</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted Average Exercise Price</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted Average Remaining Life (Years)</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Aggregate Intrinsic Value</td></tr> <tr style="vertical-align: bottom"> <td style="width: 40%; text-align: left; padding-left: 5.4pt">Outstanding and exercisable at June 30, 2019</td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">15,583,216</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">0.36</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">5.6</td><td style="width: 1%; text-align: left"> </td><td style="width: 3%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">716,653</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 5.4pt">Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">156,250,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.03</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.0</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">5,906,250</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; padding-left: 5.4pt">Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">—  </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Outstanding and exercisable at September 30, 2019</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">171,833,216</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">0.04</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">4.9</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">6,622,903</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr></table>

229377 P4Y9M18D

P4Y9M18D

P9Y6M

0.6309

0.0000

0.00

10643392

8109724

2533668

8109724

2533668

10643392

-257288

-105298

8367012

2638966

EX-101.CAL 7 bivi-20190930_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 bivi-20190930_def.xml XBRL DEFINITION FILE EX-101.LAB 9 bivi-20190930_lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock Capital in Excess of Par Value Accumulated Deficit Derivative Instrument [Axis] Stock Option [Member] Stock Option [Member] Stock Option [Member] Stock Option [Member] Stock Option [Member] Stock Option [Member] Stock Option [Member] Stock Option [Member] Preferred Stock Additional Paid-In Capital Warrant [Member] Stock Option [Member] Stock Option [Member] Stock Option [Member] Concentration Risk Benchmark [Axis] Derivative liability - Warrants [Member] Derivative Liability - Conversion Option on Convertible Debenture [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 3 [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Is Entity a Well-known Seasoned Issuer? Is Entity a Voluntary Filer? Is Entity's Reporting Status Current? Entity Filer Category Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Entity Shell Company Entity Emerging Growth Company Entity Small Business Entity Ex Transition Period Entity Incorporation, State or Country Code Entity File Number Entity Interactive Data Current Statement of Financial Position [Abstract] ASSETS CURRENT ASSETS: Cash Other Assets Total Current Assets OTHER ASSETS: Intangible Assets Goodwill Total Fixed Assets TOTAL ASSETS LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES: Accounts Payable and accrued expenses Derivative liability - warrants Derivative liability - conversion option on convertible debenture Convertible debenture - related party, net of discount $498,466 and $0 at September 30, 2019 and 2018, respectively Total Current Liabilities TOTAL LIABILITIES Commitments and contingencies STOCKHOLDERS' EQUITY Preferred stock; $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding Common stock, $0.0001 par value; 800,000,000 shares authorized at September 30, 2019 and June 30, 2019, respectively; 647,930,147 and 507,305,147 shares issued and outstanding at September 30, 2019 and June 30, 2019, respectively Additional paid in capital Accumulated deficit Total Stockholders' Equity TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY Preferred stock, par value Preferred stock, shares authorized Preferred Stock, Shares Issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common Stock Shares Issued Common stock, shares outstanding Income Statement [Abstract] OPERATING EXPENSES Amortization Research and development expenses Selling, general and administrative expenses TOTAL OPERATING EXPENSES LOSS FROM OPERATIONS OTHER EXPENSE (INCOME) Change in fair value of derivative liabilities Gain on settlement of debt Interest Expense Interest income TOTAL OTHER EXPENSE (INCOME) NET LOSS Deemed dividend NET LOSS ATTRIBUTABLE TO COMPANY STOCKHOLDERS NET LOSS PER COMMON SHARE, BASIC AND DILUTED WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING, BASIC AND DILUTED Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Net loss Adjustments to reconcile net loss to net cash to cash used by operating activities: Amortization of intangible assets Stock based compensation expense Interest expense from convertible debenture Changes in operating assets and liabilities: Other assets Accounts Payable Net cash used by operating activities CASH FLOWS FROM FINANCING ACTIVITIES: Repayment of debt Proceeds from issuance of preferred shares Proceeds from issuance of common stock and warrants Net cash provided by financing activities Net decrease in cash Cash, beginning of period Cash, end of period SUPPLEMENTAL CASH FLOW INFORMATION: Cash paid for interest Cash paid for taxes NON-CASH INVESTING AND FINANCING ACTIVITIES Conversion of preferred shares to common stock Settlement of debt by issuance of common stock Cashless exercise of warrants Deemed dividends for ratchet adjustments to warrants Deemed dividends for commitment shares Stock warrants classified as derivative liability Statement [Table] Statement [Line Items] Beginning Balance Beginning Balance, Shares Issuance of shares in a private placement Issuance of shares in a private placement (in shares) Issuance of commitment shares Issuance of commitment shares, Shares Conversion of preferred stock to common stock Conversion of preferred stock to common stock (in shares) Issuance of shares in exchange for debt settlement Issuance of shares in exchange for debt settlement, Shares Issuance of warrants in a private placement Issuance of warrants for services Stock option compensation Cashless exercise of warrants, Shares Deemed dividends for ratchet adjustment to warrants Ending Balance Ending Balance, Shares Notes to Financial Statements Background Information Liquidity and Going Concern Accounting Policies [Abstract] Significant Accounting Policies Related Party Transactions [Abstract] Intangible Assets Related Party Transactions Fair Value Disclosures [Abstract] Fair Value Measurements Share-based Payment Arrangement [Abstract] Equity Transactions Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Subsequent Events [Abstract] Subsequent Events Basis of Presentation Net Loss per Common Share Recent accounting pronouncements Significant Accounting Policies Schedule of Dilutive securities were excluded from the computation of diluted loss per share Intangible Assets Schedule of Intangible Assets Schedule of Future expected Amortization of intangible assets Schedule of Estimated Fair Value of Derivative Liability Schedule of Liabilities Measured at Fair Value Equity Transactions Schedule of Stock Option Issued Schedule of option outstanding and exercisable by exercise price Schedule of Warrants Issued Dilutive Securities excluded from the Computation of Diluted Loss Per Share Intangible Assets Intellectual Property Accumulated Amortization Intellectual Property, Net Intangible Assets 2020 2021 2022 2023 2024 2025 Thereafter Total derivatives Beginning balance at July 1, 2019 Additions to level 3 liabilities Change in in fair value of level 3 liability Transfer in and/or out of Level 3 Balance at September 30, 2019 Option Outstanding at beginning of period Option Granted EX-101.PRE 10 bivi-20190930_pre.xml XBRL PRESENTATION FILE EX-101.SCH 11 bivi-20190930.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Balance Sheet (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Balance Sheet (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Statements of Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Background Information link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Liquidity and Going Concern link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Equity Transactions link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Equity Transactions (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Intangible Assets (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Fair Value Measurements (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Equity Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Equity Transactions (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Equity Transactions (Details 3) link:presentationLink link:calculationLink link:definitionLink XML 12 R11.htm IDEA: XBRL DOCUMENT

Related Party Transactions

3 Months Ended

Sep. 30, 2019

Related Party Transactions

5.	Related Party Transactions

Equity Transactions with Acuitas

Pursuant to a letter agreement dated June 24, 2019, Acuitas agreed to modify its existing rights under the Purchase Agreement so that:

•		Acuitas agreed to immediately exchange its existing 200,833,333 Warrants for common stock such that it will have effectively exercised its Warrants in full pursuant to a cashless exercise thereof at an assumed current market price of $0.36 per share and, as a result received an aggregate of 95% of the shares covered thereby, or 190,761,666 shares of common stock;

•		Acuitas agreed to (i) waive its rights to a 50% adjustment of the purchase price of the Preferred Stock in the Initial Sale, the exercise price of the Warrants and the price per share in the Subsequent Sale in the event of certain reductions in the useful life of our current intellectual property rights, and (ii) effectively exercise its rights to purchase securities in a Subsequent Sale pursuant to a “cashless purchase” at an assumed current market price of approximately $0.09 per share, conditioned in each case on the listing of our common stock on Nasdaq or the raising of $2.0 million in additional funds in the form of another securities offering, in either case not later than November 30, 2019, which will result Acuitas having irrevocably waived its rights to an adjustment in the purchase price of the Preferred Stock in the Initial Sale and the exercise price of the Warrants and the purchase price of per share in the Subsequent Sale upon the issuance by us of an aggregate of 167,494,750 shares of common stock (the “Subsequent Sale Shares”) to Acuitas, which is expected to occur concurrently with the closing of our potential public offering and listing on Nasdaq;

•		Acuitas shall in exchange for the foregoing agreements and waivers have the option to purchase additional shares of common stock and warrants to purchase one share of common stock for each share of common stock purchased during the period from September 1, 2019 to November 30, 2019 at the then-effective purchase price of the Preferred Stock in the Initial Sale (the “Funding Option”), provided that any shares issued pursuant to any exercise of the Funding Option will reduce share-for-share the amount of shares issued pursuant to the deemed exercise of its rights to purchase securities in a Subsequent Sale mentioned above.

Convertible Debenture Transaction with Acuitas

The issuance of 140,625,000 shares of the Company’s commons stock and warrants to purchase an equal amount number of shares, to its controlling stockholder for the Bridge Financing was accounted for as a deemed dividend due to its related party nature and $17.1 million representing the debt discount, net of the outstanding draw amount; was recorded in accumulated deficit for the three months ended September 30, 2019, accordingly. (See accompanied Condensed Statements of Changes in Stockholders’ (Deficit) Equity). A debt discount of $500,000 against the debenture was recorded which will be amortized over the term of the debenture using the effective interest method. The Company recognized amortization of this discount in the amount of $1,534 for the three-month period ended September 30, 2019.

Pursuant to an amendment to the 2019 Purchase Agreement dated October 9, 2019, Acuitas agreed to modify its existing rights under the 2019 Purchase Agreement so that:

	•	The Commitment Warrants (and related warrants issued upon the first draw under the Debenture) were replaced with warrants having similar terms, but which are automatically exercised upon the closing of the offering at an exercise price equal to the par value of the common stock;

	•	Acuitas' existing rights under the Purchase Agreement dated July 3, 2018 with the Company were further amended so that the number of Subsequent Sale Shares would be multiplied by four (in lieu of the changes to the Purchase Agreement originally provided for in the 2019 Purchase Agreement); and

	•	The provisions of the 2019 Purchase Agreement providing that, should the underwriters in the offering exercise their option to purchase additional securities during the 45 days following closing and the issuance of such securities would result in Acuitas’ beneficial ownership (on a fully diluted basis) of shares of common stock being below 60%, Acuitas will be issued a number of additional shares of common stock and warrants having the same terms as the Commitment Warrants to result in its beneficial ownership (on a fully diluted basis) of shares of common stock equaling 60% have been modified such that, upon the exercise of such option by the underwriters, the Company will issue to Acuitas a number of securities that will result in Acuitas’ fully diluted beneficial ownership after the exercise of such option being the same as prior thereto.

XML 13 R15.htm IDEA: XBRL DOCUMENT

Subsequent Events

3 Months Ended

Sep. 30, 2019

Subsequent Events [Abstract]

Subsequent Events

9.	Subsequent Events

XML 14 R19.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Tables)

3 Months Ended

Sep. 30, 2019

Fair Value Disclosures [Abstract]

Schedule of Estimated Fair Value of Derivative Liability

At September 30, 2019, the estimated fair value of derivative liabilities measured on a recurring basis are as follows:

	Fair Value Measurements at
	September 30, 2019
	Level 1		Level 2		Level 3		Total

Derivative liability – Warrants	$	—	$	—	$	8,109,724	$	8,109,724
Derivative liability -Conversion option on convertible debenture		—		—		2,533,668		2,533,668
Total derivatives	$	—	$	—	$	10,643,392	$	10,643,392

Schedule of Liabilities Measured at Fair Value

The following table presents the activity for liabilities measured at fair value using unobservable inputs for the three months ended September 30, 2019:

	Derivative liabilities - Warrants			Derivative liability - Conversion Option on Convertible Debenture

Beginning balance at July 1, 2019	$	—		$	—
Additions to level 3 liabilities		8,367,012			2,638,966
Change in in fair value of level 3 liability		(257,288	)		(105,298	)
Transfer in and/or out of Level 3		—			—
Balance at September 30, 2019	$	8,109,724		$	2,533,668

XML 15 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Sep. 30, 2019	Nov. 18, 2019
Document And Entity Information
Entity Registrant Name	BIOVIE INC.
Entity Central Index Key	0001580149
Document Type	10-Q
Document Period End Date	Sep. 30, 2019
Amendment Flag	false
Current Fiscal Year End Date	--06-30
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		647,930,147
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2020
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Incorporation, State or Country Code	NV
Entity File Number	001-39015
Entity Interactive Data Current	Yes

XML 16 R5.htm IDEA: XBRL DOCUMENT

Condensed Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (3,821,227)	$ (439,871)
Adjustments to reconcile net loss to net cash to cash used by operating activities:
Amortization of intangible assets	57,344	57,344
Stock based compensation expense		3,412
Interest expense from convertible debenture	3,477,204
Change in fair value of derivative liabilities	(362,586)
Changes in operating assets and liabilities:
Other assets	(182,229)
Accounts Payable	240,580	(62,767)
Net cash used by operating activities	(590,914)	(441,882)
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayment of debt		(508,300)
Proceeds from issuance of preferred shares		3,040,000
Proceeds from issuance of common stock and warrants	500,000
Net cash provided by financing activities	500,000	2,531,700
Net decrease in cash	(90,914)	2,089,818
Cash, beginning of period	339,923	45,800
Cash, end of period	249,009	2,135,619
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for interest	411
Cash paid for taxes
NON-CASH INVESTING AND FINANCING ACTIVITIES
Conversion of preferred shares to common stock		3,200,000
Settlement of debt by issuance of common stock		1,150,135
Cashless exercise of warrants
Deemed dividends for ratchet adjustments to warrants		48,659
Deemed dividends for commitment shares	17,099,058	48,659
Stock warrants classified as derivative liability	$ 7,530,308

XML 17 R9.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies

3 Months Ended

Sep. 30, 2019

Accounting Policies [Abstract]

Significant Accounting Policies

3.	Significant Accounting Policies

Basis of Presentation – Interim Financial Information

For a summary of significant accounting policies, see the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2019 filed with the SEC on September 27, 2019.

Net Loss per Common Share

The table below shows the number of outstanding stock options and warrants as of September 30, 2019 and 2018:

	September 30, 2019		September 30, 2018
	Number of Shares		Number of Shares
Stock Options		7,250,000		5,150,000
Warrants		171,833,216		216,441,548
Total		179,083,216		221,591,548

Recent accounting pronouncements

XML 18 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 19 R23.htm IDEA: XBRL DOCUMENT

Intangible Assets (Details 2) - USD ($)	Sep. 30, 2019	Jun. 30, 2019
Disclosure Intangible Assets Details 2Abstract
2020	$ 172,032
2021	229,377
2022	229,377
2023	229,377
2024	229,377
2025	229,377
Thereafter	178,342
Intellectual Property, Net	$ 1,497,259	$ 1,554,603

XML 20 R27.htm IDEA: XBRL DOCUMENT

Equity Transactions (Details 2) - Stock Option [Member] - $ / shares	3 Months Ended
	Sep. 30, 2019	Jun. 30, 2019
Exercise Price	$ 0.03
Option Outstanding	700,000
Weighted Average Contractual Life	4 years 3 months 18 days
Option Excersiable	700,000
Exercise Price	$ 0.05
Option Outstanding	1,300,000
Weighted Average Contractual Life	4 years 4 months 24 days
Option Excersiable	1,300,000
Exercise Price	$ 0.06
Option Outstanding	3,100,000
Weighted Average Contractual Life	6 years 4 months 24 days
Option Excersiable	3,100,000
Exercise Price	$ 0.07
Option Outstanding	100,000
Weighted Average Contractual Life	4 years
Option Excersiable	100,000
Exercise Price	$ 0.10
Option Outstanding	500,000
Weighted Average Contractual Life	3 years 3 months 18 days
Option Excersiable	500,000
Exercise Price	$ 0.20
Option Outstanding	200,000
Weighted Average Contractual Life	3 years
Option Excersiable	200,000
Exercise Price	$ 0.21
Option Outstanding	550,000
Weighted Average Contractual Life	2 years 7 months 6 days
Option Excersiable	550,000
Exercise Price	$ 0.22
Option Outstanding	100,000
Weighted Average Contractual Life	2 years 6 months
Option Excersiable	100,000
Exercise Price	$ 0.23
Option Outstanding	200,000
Weighted Average Contractual Life	2 years 10 months 24 days
Option Excersiable	200,000
Exercise Price	$ 0.25
Option Outstanding	500,000
Weighted Average Contractual Life	2 years 1 month 6 days
Option Excersiable	500,000
Exercise Price	$ 0.10	$ 0.10
Option Outstanding	7,250,000	7,250,000
Weighted Average Contractual Life	5 years 2 months 12 days
Option Excersiable	7,250,000

ZIP 21 0001520138-19-000474-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001520138-19-000474-xbrl.zip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end EXCEL 22 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

XML 25 R26.htm IDEA: XBRL DOCUMENT v3.19.3

Equity Transactions (Details) - Stock Option [Member] - USD ($)
3 Months Ended

Sep. 30, 2019

Sep. 30, 2018

Option Outstanding at beginning of period 7,250,000

Option Granted

Option Exercised

Option Outstanding at end of period 7,250,000

Option Excersiable at end of period 7,250,000

Outstanding Weighted Average Exercise Price at the beginning of period $ 0.10

Weighted Average Exercise Price, Granted

Weighted Average Exercise Price, Exercised

Outstanding Weighted Average Exercise Price at the end of period 0.10

Excersiable Weighted Average Exercise Price at the end of period $ 0.10

Weighted Average Remaining Contractual Term at the beginning of period 5 years 2 months 12 days

Weighted Average Remaining Contractual Term at the end 4 years 9 months 18 days

Excersiable Weighted Average Remaining Contractual Term at the end of period 4 years 9 months 18 days

Aggregate Intrinsic Value Outstanding at beginning of period $ 87,480

Granted

Options Exercised or Forfeited

Aggregate Intrinsic Value Outstanding at end of period 87,480

Aggregate Intrinsic Value Exercisable $ 87,480

Expected life of options (In years) 9 years 6 months

Expected volatility 63.09%

Risk free interest rate 0.00%

Dividend Yield 0.00%

X

- Definition
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term
+ References
No definition available.
+ Details

Name: bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm4

Namespace Prefix: bivi_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which option holders acquired shares when converting their stock options into shares.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.D.2)
-URI http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 26 R18.htm IDEA: XBRL DOCUMENT v3.19.3

Intangible Assets (Tables)
3 Months Ended

Sep. 30, 2019

Disclosure Intangible Assets Tables Abstract

Schedule of Intangible Assets
The following is a summary of the intangible assets as of September 30, 2019 and June 30, 2019:

September 30, 2019 June 30, 2019

Intellectual Property $ 2,293,770 $ 2,293,770

Less Accumulated Amortization (796,511 ) (739,167 )

Intellectual Property, Net $ 1,497,259 $ 1,554,603

Schedule of Future expected Amortization of intangible assets
Estimated future amortization expense is as follows:

Year ending June 30, 2020 (Remaining nine months) $ 172,032

2021 229,377

2022 229,377

2023 229,377

2024 229,377

2025 229,377

Thereafter 178,342

$ 1,497,259

X

- References
No definition available.
+ Details

Name: bivi_DisclosureIntangibleAssetsTablesAbstract

Namespace Prefix: bivi_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275
+ Details

Name: us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 27 R10.htm IDEA: XBRL DOCUMENT v3.19.3

Intangible Assets
3 Months Ended

Sep. 30, 2019

Related Party Transactions [Abstract]

Intangible Assets

4. Intangible Assets

The Company’s intangible assets consist of intellectual property acquired from LAP Pharma, Inc. and are amortized over their estimated useful lives. The following is a summary of the intangible assets as of September 30, 2019 and June 30, 2019:

September 30, 2019 June 30, 2019

Intellectual Property $ 2,293,770 $ 2,293,770

Less Accumulated Amortization (796,511 ) (739,167 )

Intellectual Property, Net $ 1,497,259 $ 1,554,603

Amortization expense for the three-month period ended September 30, 2019 and 2018 was $57,344 and $57,344 respectively.

Estimated future amortization expense is as follows:

Year ending June 30, 2020 (Remaining nine months) $ 172,032

2021 229,377

2022 229,377

2023 229,377

2024 229,377

2025 229,377

Thereafter 178,342

$ 1,497,259

X

- Definition
The entire disclosure for all or part of the information related to intangible assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-URI http://asc.fasb.org/topic&trid=2144416
+ Details

Name: us-gaap_IntangibleAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 28 R14.htm IDEA: XBRL DOCUMENT v3.19.3

Commitments and Contingencies
3 Months Ended

Sep. 30, 2019

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

8. Commitments and Contingencies

Office Lease

On July 1, 2019, the Company’s office moved with Acuitas’ new offices to 2120 Colorado Avenue Ste 230, Santa Monica, CA 90404. There is no lease agreement for the new premises and the Company continues to accrue monthly lease payments of $1,000 for the new office under the terms of the previous month-to-month lease for the previous premises which may be cancelled upon 30 days’ written notice.

Challenge to US Patent

On April 30, 2018, we received notice that Mallinckrodt had petitioned the U.S. Patent and Trademark Office (“USPTO”) to institute an Inter Partes Review of our U.S. Patent No. 9,655,945 titled “Treatment of Ascites” (the “’945 patent”). Inter Partes Review is a trial proceeding conducted with the USPTO Patent Trial and Appeal Board (PTAB) to review the patentability of one or more claims of a patent. Such review is limited to grounds of novelty and obviousness on the basis of prior art consisting of patents and printed publications.

On November 13, 2019, the Patent Trial and Appeal Board of the United States Patent and Trademark Office (the “Board”) issued a written decision in the inter partes review (“IPR”) action that was brought by Mallinckrodt Pharmaceuticals Ireland Limited (“Mallinckrodt”) against BioVie Inc. (“BioVie” or “Company”). In that action, Mallinckrodt sought to invalidate BioVie’s patent (U.S. Pat. No. 9,655,945, “Treatment of Ascites”) (the “’945 Patent”). In its decision, the Board determined that all claims of the ‘945 Patent were not patentable because they were either anticipated or obvious in light of prior art. The Board also denied BioVie’s Motion to Amend the claims on similar grounds. The result of the Board’s decision is that the ‘945 patent is no longer valid or enforceable. Acuitas Group Holdings, LLC was aware of this patent challenge when it purchased a majority ownership interest in the company in July 2018.

BioVie is evaluating the Board’s decision to determine if it will request a rehearing by the Board or appeal the Board’s decision to the U.S. Court of Appeals for the Federal Circuit. This ruling is unrelated to the Company’s Orphan drug designations for ascites and hepatorenal syndrome (“HRS”), which remain unchanged. An Orphan drug that is first-to-market typically receives 7 years of market exclusivity in the United States for the designated use(s). In addition, the ruling does not affect the Company’s rights in its pending patent application directed to proprietary liquid formulations of terlipressin for use in its planned Phase 2b/3 trial, subject to FDA clearance, which could eventually provide up to 20 years of patent coverage in each country in which the Company seeks patent protection, such as the United States, if a patent issues from a patent application according to the patent laws of each issuing country.

At September 30, 2019, no adjustments or accruals have been reflected in our financial statements related to this matter. (See Note 9 – Subsequent events.)

Royalty Agreements

Pursuant to the Agreement and Plan of Merger entered into on April 11, 2016 between our predecessor entities, LAT Pharma LLC and NanoAntibiotics, Inc., BioVie is obligated to pay a low single digit royalty on net sales of BIV201 (continuous infusion terlipressin) to be shared among LAT Pharma Members, PharmaIn Corporation, and The Barrett Edge, Inc.

The Company and PharmaIN Corporation, LAT Pharma’s former partner focused on the development of new modified drug candidates in the same therapeutic field but not including BIV201, had agreed to pay royalties equal to less than 1% of future net sales of each company's ascites drug development programs, or if such program is licensed to a third party, less than 5% of each company's net license revenues. On December 24, 2018, the Company returned its partial ownership rights to the PharmaIN modified terlipressin development program and simultaneously paid the remaining balance due on a related debt. PharmaIN, Corp. rights to our program remain unchanged.

Pursuant to the Technology Transfer Agreement entered into on July 25, 2016 between BioVie and the University of Padova (Italy), BioVie is obligated to pay a low single digit royalty on net sales of all terlipressin products covered by US patent no. 9,655,645 and any future foreign issuances capped at a maximum of $200,000 per year.

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for commitments and contingencies.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-URI http://asc.fasb.org/topic&trid=2127136

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-URI http://asc.fasb.org/topic&trid=2144648
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 29 R8.htm IDEA: XBRL DOCUMENT v3.19.3

Liquidity and Going Concern
3 Months Ended

Sep. 30, 2019

Notes to Financial Statements

Liquidity and Going Concern

2. Liquidity and Going Concern

The Company’s operations are subject to a number of factors that can affect its operating results and financial conditions. Such factors include, but are not limited to: the results of clinical testing and trial activities of the Company’s products, the Company’s ability to obtain regulatory approval to market its products, competition from products manufactured and sold or being developed by other companies, the price of, and demand for, Company products, the Company’s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, and the Company’s ability to raise capital. The Company’s financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As of September 30, 2019, the Company had an accumulated deficit of $28.2 million and as a development stage enterprise, the Company expects substantial losses in future periods. The accompanying interim financial statements were prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company’s future operations are dependent on the success of the Company’s ongoing development and commercialization effort, as well as continuing to secure additional financing.

On September 24, 2019, the Company entered into a Securities Purchase Agreement with its controlling stockholder regarding bridge financing (the “Bridge Financing”) in the form of up to $2.0 million in convertible debt and warrants, of which $500,000 has been drawn as of September 30, 2019. Amounts borrowed under the Bridge Financing must be repaid with the proceeds of our potential public offering of equity securities referred to below. The availability of additional draws under the Bridge Financing is under further discussion with the controlling stockholder in light of delays in the timing of the potential public offering. As further discussed below, the Company is pursuing various options to raise further financing to continue the testing and development of its product. If the Company is not successful in raising additional funds it may reduce its monthly spend and potentially delay the implementation of the larger scale Phase 2b Clinical trial until sufficient funding is secured.

Additionally, in April 2019, to facilitate our planned up listing to the NASDAQ Stock Market and related potential future issuances and sales of our equity securities for ordinary corporate finance and general corporate purposes and as recommended by our Board of Directors (“Board”), our stockholders approved an amendment to our Articles of Incorporation to effect a reverse split of our outstanding Class A common stock in the range of 50:1 to 200:1, as determined by our Board. Following that approval, we filed a Registration Statement on Form S-1 (Registration No. 333-231136) (the “S-1 Registration Statement”) pursuant to which we anticipate completing an offering of our equity securities with proceeds sufficient to enable the launch and completion of the BIV201 Phase 2b study and fund our internal operations for at least the next twelve months. There can be no assurance, however, that we will successfully complete an offering thereunder on the terms contemplated by the S-1 Registration Statement or on any commercially reasonable terms.

The future viability of the Company is largely dependent upon its ability to raise additional capital to finance its operations. Management expects that future sources of funding may include sales of equity, obtaining loans, or other strategic transactions. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient financing on terms acceptable to the Company, if at all, to fund continuing operations. These circumstances raise substantial doubt on the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

X

- Definition
Liquidity [Text Block]
+ References
No definition available.
+ Details

Name: bivi_LiquidityTextBlock

Namespace Prefix: bivi_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: bivi_NotesToFinancialStatementsAbstract

Namespace Prefix: bivi_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 30 R4.htm IDEA: XBRL DOCUMENT v3.19.3

Condensed Statements of Operations (Unaudited) - USD ($)
3 Months Ended

Sep. 30, 2019

Sep. 30, 2018

OPERATING EXPENSES

Amortization $ 57,344 $ 57,344

Research and development expenses 341,501 194,521

Selling, general and administrative expenses 307,373 239,562

TOTAL OPERATING EXPENSES 706,218 491,427

LOSS FROM OPERATIONS (706,218) (491,427)

OTHER EXPENSE (INCOME)

Change in fair value of derivative liabilities (362,586)

Gain on settlement of debt (51,400)

Interest Expense 3,477,615 272

Interest income (20) (428)

TOTAL OTHER EXPENSE (INCOME) 3,115,009 (51,556)

NET LOSS (3,821,227) (439,871)

Deemed dividend 17,099,058 48,659

NET LOSS ATTRIBUTABLE TO COMPANY STOCKHOLDERS $ (20,920,285) $ (488,530)

NET LOSS PER COMMON SHARE, BASIC AND DILUTED $ (0.04) $ 0.00

WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING, BASIC AND DILUTED 516,577,125 309,279,009

X

- Definition
Deemed Dividend
+ References
No definition available.
+ Details

Name: bivi_DeemedDividend

Namespace Prefix: bivi_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Total Other Expense Income.
+ References
No definition available.
+ Details

Name: bivi_TotalOtherExpenseIncome

Namespace Prefix: bivi_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274
+ Details

Name: us-gaap_AmortizationOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256
+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The difference between the book value and the sale price of options, swaps, futures, forward contracts, and other derivative instruments. This element refers to the gain (loss) included in earnings.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.13(h))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260
+ Details

Name: us-gaap_GainLossOnSaleOfDerivatives

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 50
-Section 40
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 50
-Section 40
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_GainsLossesOnExtinguishmentOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.20)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_IncomeLossAttributableToParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (210.5-03(11))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.9)
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260
+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of interest income earned from interest bearing assets classified as other.
+ References
No definition available.
+ Details

Name: us-gaap_InterestIncomeOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OtherExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686
+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 30
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_SellingGeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).
+ References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 31 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3 html 68 234 1 false 19 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://nanoantibiotics.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Balance Sheet (Unaudited) Sheet http://nanoantibiotics.com/role/BalanceSheet Condensed Balance Sheet (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Condensed Balance Sheet (Unaudited) (Parenthetical) Sheet http://nanoantibiotics.com/role/BalanceSheetParenthetical Condensed Balance Sheet (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Statements of Operations (Unaudited) Sheet http://nanoantibiotics.com/role/StatementsOfOperations Condensed Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Statements of Cash Flows (Unaudited) Sheet http://nanoantibiotics.com/role/StatementsOfCashFlows Condensed Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Statements of Stockholders' Equity (Unaudited) Sheet http://nanoantibiotics.com/role/StatementsOfStockholdersEquity Condensed Statements of Stockholders' Equity (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - Background Information Sheet http://nanoantibiotics.com/role/BackgroundInformation Background Information Notes 7 false false R8.htm 00000008 - Disclosure - Liquidity and Going Concern Sheet http://nanoantibiotics.com/role/LiquidityAndGoingConcern Liquidity and Going Concern Notes 8 false false R9.htm 00000009 - Disclosure - Significant Accounting Policies Sheet http://nanoantibiotics.com/role/SignificantAccountingPolicies Significant Accounting Policies Notes 9 false false R10.htm 00000010 - Disclosure - Intangible Assets Sheet http://nanoantibiotics.com/role/IntangibleAssets Intangible Assets Notes 10 false false R11.htm 00000011 - Disclosure - Related Party Transactions Sheet http://nanoantibiotics.com/role/RelatedPartyTransactions Related Party Transactions Notes 11 false false R12.htm 00000012 - Disclosure - Fair Value Measurements Sheet http://nanoantibiotics.com/role/FairValueMeasurements Fair Value Measurements Notes 12 false false R13.htm 00000013 - Disclosure - Equity Transactions Sheet http://nanoantibiotics.com/role/EquityTransactions Equity Transactions Notes 13 false false R14.htm 00000014 - Disclosure - Commitments and Contingencies Sheet http://nanoantibiotics.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 14 false false R15.htm 00000015 - Disclosure - Subsequent Events Sheet http://nanoantibiotics.com/role/SubsequentEvents Subsequent Events Notes 15 false false R16.htm 00000016 - Disclosure - Significant Accounting Policies (Policies) Sheet http://nanoantibiotics.com/role/SignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Policies http://nanoantibiotics.com/role/SignificantAccountingPolicies 16 false false R17.htm 00000017 - Disclosure - Significant Accounting Policies (Tables) Sheet http://nanoantibiotics.com/role/SignificantAccountingPoliciesTables Significant Accounting Policies (Tables) Tables http://nanoantibiotics.com/role/SignificantAccountingPolicies 17 false false R18.htm 00000018 - Disclosure - Intangible Assets (Tables) Sheet http://nanoantibiotics.com/role/IntangibleAssetsTables Intangible Assets (Tables) Tables http://nanoantibiotics.com/role/IntangibleAssets 18 false false R19.htm 00000019 - Disclosure - Fair Value Measurements (Tables) Sheet http://nanoantibiotics.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://nanoantibiotics.com/role/FairValueMeasurements 19 false false R20.htm 00000020 - Disclosure - Equity Transactions (Tables) Sheet http://nanoantibiotics.com/role/EquityTransactionsTables Equity Transactions (Tables) Tables http://nanoantibiotics.com/role/EquityTransactions 20 false false R21.htm 00000021 - Disclosure - Significant Accounting Policies (Details) Sheet http://nanoantibiotics.com/role/SignificantAccountingPoliciesDetails Significant Accounting Policies (Details) Details http://nanoantibiotics.com/role/SignificantAccountingPoliciesTables 21 false false R22.htm 00000022 - Disclosure - Intangible Assets (Details) Sheet http://nanoantibiotics.com/role/IntangibleAssetsDetails Intangible Assets (Details) Details http://nanoantibiotics.com/role/IntangibleAssetsTables 22 false false R23.htm 00000023 - Disclosure - Intangible Assets (Details 2) Sheet http://nanoantibiotics.com/role/IntangibleAssetsDetails2 Intangible Assets (Details 2) Details http://nanoantibiotics.com/role/IntangibleAssetsTables 23 false false R24.htm 00000024 - Disclosure - Fair Value Measurements (Details) Sheet http://nanoantibiotics.com/role/FairValueMeasurementsDetails Fair Value Measurements (Details) Details http://nanoantibiotics.com/role/FairValueMeasurementsTables 24 false false R25.htm 00000025 - Disclosure - Fair Value Measurements (Details 2) Sheet http://nanoantibiotics.com/role/FairValueMeasurementsDetails2 Fair Value Measurements (Details 2) Details http://nanoantibiotics.com/role/FairValueMeasurementsTables 25 false false R26.htm 00000026 - Disclosure - Equity Transactions (Details) Sheet http://nanoantibiotics.com/role/EquityTransactionsDetails Equity Transactions (Details) Details http://nanoantibiotics.com/role/EquityTransactionsTables 26 false false R27.htm 00000027 - Disclosure - Equity Transactions (Details 2) Sheet http://nanoantibiotics.com/role/EquityTransactionsDetails2 Equity Transactions (Details 2) Details http://nanoantibiotics.com/role/EquityTransactionsTables 27 false false R28.htm 00000028 - Disclosure - Equity Transactions (Details 3) Sheet http://nanoantibiotics.com/role/EquityTransactionsDetails3 Equity Transactions (Details 3) Details http://nanoantibiotics.com/role/EquityTransactionsTables 28 false false All Reports Book All Reports bivi-20190930.xml bivi-20190930.xsd bivi-20190930_cal.xml bivi-20190930_def.xml bivi-20190930_lab.xml bivi-20190930_pre.xml http://fasb.org/us-gaap/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 true true XML 32 R20.htm IDEA: XBRL DOCUMENT v3.19.3

Equity Transactions (Tables)
3 Months Ended

Sep. 30, 2019

Disclosure Stock Options Tables Abstract

Schedule of Stock Option Issued
The following table summarizes the activity relating to the Company’s stock options for the three months ended September 30, 2019:

Options Weighted-Average Exercise Price Weighted Remaining Average Contractual Term Aggregate Intrinsic Value

Outstanding at June 30, 2019 7,250,000 $ 0.10 5.2 $ 87,480

Granted —   —   —   —

Options Exercised or Forfeited —   —   —   —

Outstanding at September 30, 2019 7,250,000 $ 0.10 4.8 $ 87,480

Exercisable at  September 30, 2019 7,250,000 $ 0.10 4.8 $ 87,480

The pricing model reflected the following weighted-average assumptions for the three months ended September 30, 2018:

September 30 2019 September 30 2018

Expected life of options (In years) —   9.5

Expected volatility —   63.09 %

Risk free interest rate —   0.00 %

Dividend Yield —   0 %

Schedule of option outstanding and exercisable by exercise price
The following is a summary of stock options outstanding and exercisable by exercise price as of September 30, 2019:

Exercise Price Outstanding Weighted Average Contract Life Exercisable

$ 0.03 700,000 4.3 700,000

$ 0.05 1,300,000 4.4 1,300,000

$ 0.06 3,100,000 6.4 3,100,000

$ 0.07 100,000 4.0 100,000

$ 0.10 500,000 3.3 500,000

$ 0.20 200,000 3.0 200,000

$ 0.21 550,000 2.6 550,000

$ 0.22 100,000 2.5 100,000

$ 0.23 200,000 2.9 200,000

$ 0.25 500,000 2.1 500,000

Total 7,250,000 7,250,000

Schedule of Warrants Issued
The following table summarizes the warrants activity during the three months ended September 30, 2019:

Number of Shares Weighted Average Exercise Price Weighted Average Remaining Life (Years) Aggregate Intrinsic Value

Outstanding and exercisable at June 30, 2019 15,583,216 $ 0.36 5.6 $ 716,653

Granted 156,250,000 $ 0.03 5.0 $ 5,906,250

Expired —   $ —   —   $ —

Outstanding and exercisable at September 30, 2019 171,833,216 $ 0.04 4.9 $ 6,622,903

X

- References
No definition available.
+ Details

Name: bivi_DisclosureStockOptionsTablesAbstract

Namespace Prefix: bivi_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the change in common stock outstanding.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the number and weighted-average grant date fair value for outstanding performance shares.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationPerformanceSharesAwardOutstandingActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R24.htm IDEA: XBRL DOCUMENT v3.19.3

Fair Value Measurements (Details) - USD ($)

Sep. 30, 2019

Jun. 30, 2019

Total derivatives $ 10,643,392

Fair Value, Inputs, Level 3 [Member]

Total derivatives 10,643,392

Derivative liability - Warrants [Member]

Total derivatives 8,109,724

Derivative liability - Warrants [Member] | Fair Value, Inputs, Level 3 [Member]

Total derivatives 8,109,724

Derivative Liability - Conversion Option on Convertible Debenture [Member]

Total derivatives 2,533,668

Derivative Liability - Conversion Option on Convertible Debenture [Member] | Fair Value, Inputs, Level 3 [Member]

Total derivatives $ 2,533,668

X

- Definition
Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=118260190&loc=d3e13433-108611

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313
+ Details

Name: us-gaap_DerivativeLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByBenchmarkAxis=bivi_DerivativeLiabilityWarrantsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByBenchmarkAxis=bivi_DerivativeLiabilityConversionOptionOnConvertibleDebentureMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 34 R28.htm IDEA: XBRL DOCUMENT v3.19.3

Equity Transactions (Details 3) - Warrant [Member]
3 Months Ended

Sep. 30, 2019

USD ($)

$ / shares

shares

Warrant Outstanding at the beginning of the year | shares 15,583,216

Warrant Granted | shares 156,250,000

Warrant Expired | shares

Warrant Exercised | shares 171,833,216

Weighted Average Exercise Price at the beginning of the year | $ / shares $ 0.36

Weighted Average Exercise Price, Granted | $ / shares 0.03

Weighted Average Exercise Price, Expired | $ / shares

Weighted Average Exercise Price, Exercised | $ / shares $ 0.04

Weighted Average Remaining Life at the beginning of the year 5 years

Weighted Average Remaining Life, Granted 5 years 3 months 18 days

Weighted Average Remaining Life at the end of year 5 years 3 months 18 days

Aggregate Intrinsic Value Outstanding at beginning of period | $ $ 716,653

Aggregate Intrinsic Value, Granted | $ 5,906,250

Aggregate Intrinsic Value Outstanding at end of period | $ $ 6,622,903

X

- Definition
Per share weighted average intrinsic value of equity-based compensation awards excersied. Excludes stock and unit options.
+ References
No definition available.
+ Details

Name: bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue

Namespace Prefix: bivi_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Granted, Weighted Average Remaining Contractual Terms
+ References
No definition available.
+ Details

Name: bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1

Namespace Prefix: bivi_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms
+ References
No definition available.
+ Details

Name: bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms3

Namespace Prefix: bivi_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Per share or unit weighted-average intrinsic value of award forfeited under share-based payment arrangement. Excludes share and unit options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(3)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Per share or unit weighted-average intrinsic value of award granted under share-based payment arrangement. Excludes share and unit options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Per share or unit weighted-average intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The net total number of shares (or other type of equity) under an equity-based award plan, other than a stock option plan, that were granted, vested and forfeited during the reporting period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 35 R12.htm IDEA: XBRL DOCUMENT v3.19.3

Fair Value Measurements
3 Months Ended

Sep. 30, 2019

Fair Value Disclosures [Abstract]

Fair Value Measurements

6. Fair Value Measurements

At September 30, 2019, the estimated fair value of derivative liabilities measured on a recurring basis are as follows:

Fair Value Measurements at

September 30, 2019

Level 1 Level 2 Level 3 Total

Derivative liability – Warrants $ —   $ —   $ 8,109,724 $ 8,109,724

Derivative liability -Conversion option on convertible debenture —   —   2,533,668 2,533,668

   Total derivatives $ —   $ —   $ 10,643,392 $ 10,643,392

The following table presents the activity for liabilities measured at fair value using unobservable inputs for the three months ended September 30, 2019:

Derivative liabilities - Warrants Derivative liability - Conversion Option on Convertible Debenture

Beginning balance at July 1, 2019 $ —   $ —

Additions to level 3 liabilities 8,367,012 2,638,966

Change in in fair value of level 3 liability (257,288 ) (105,298 )

Transfer in and/or out of Level 3 —   —

Balance at September 30, 2019 $ 8,109,724 $ 2,533,668

Derivative liability – Warrants

The Company accounts for stock purchase warrants as either equity instruments or derivative liabilities depending on the specific terms of the warrant agreements. Under applicable accounting guidance, stock warrants that are precluded from being indexed to the Company’s own stock because of full-rachet anti-dilution provisions or the adjustments to the strike price due to an occurrence of a future event; are accounted for as derivative financial instruments. The stock warrants issued September 24, 2019 were not considered indexed to the Company’s own stock because of the adjustment to strike price, an occurrence of a future event such as the Company’s pending capital raise.

The warrants associated with the level 3 liability were issued on September 24, 2019 and were valued using the Black-Scholes-Merton model with the following assumptions: stock price of $0.0716, exercise price of $0.032, term of 5 years expiring September 2024, volatility of 71.44%, dividend yield of 0%, and risk-free interest rate of 1.52%. The valuation at September 30, 2019 used the following assumptions: stock price of $0.0698, exercise price of $0.032, term of 5 year expiring September 2024, volatility of 71.42%, dividend yield of 0%, and risk-free interest rate of 1.55%. (See note 5 “Related Party Transactions – Convertible debenture transactions”)

Derivative liability – Conversion option in convertible debenture

The Company valued the conversion option of the $2 million 10% OID Convertible Delayed Draw Debenture which may be convertible into shares of common stock at $0.032 per share prior to the completion of an offering or, subsequent to the closing of the offering, the lower of $0.032 or 80% of the offering price per unit to the public in this offering and are mandatorily redeemable upon such closing at 100% of the accrued principal amount and unpaid interest to the date of redemption. (See note 5 “Related Party Transactions – Convertible debenture transactions with Acuitas” as of September 24, 2019). The conversion option was valued on September 24, 2019 using the Black Scholes-Mertons model with the following assumptions: stock price of $0.0716, conversion price of $0.032, term of 1 year expiring September 2020, volatility of 75.48%, dividend yield of 0%, and risk-free interest rate of 1.78%. The valuation at September 30, 2019 used the following assumptions: stock price of $0.0698, conversion price of $0.032, term of 1 year expiring September 2020, volatility of 75.5%, dividend yield of 0%, and risk-free interest rate of 1.75%.

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 36 R16.htm IDEA: XBRL DOCUMENT v3.19.3

Significant Accounting Policies (Policies)
3 Months Ended

Sep. 30, 2019

Accounting Policies [Abstract]

Basis of Presentation
Basis of Presentation – Interim Financial Information

The accompanying unaudited interim financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United State of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities Exchange Commission for Interim Reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The unaudited interim financial statements furnished reflect all adjustments (consisting of normal recurring accruals) that are, in the opinion of management, considered necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. The condensed balance sheet at June 30, 2019 was derived from audited annual financial statements but does not contain all the footnote disclosures from the annual financial statements. The accompanying financial statements and information included under the heading: “Management’s Discussion and Analysis of Financial Condition and Results of Operations” should be read in conjunction with our Company’s audited financial statements and related notes included in our Company’s Form 10-K for the year ended June 30, 2019 filed with the SEC on September 27, 2019.

For a summary of significant accounting policies, see the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2019 filed with the SEC on September 27, 2019.

Net Loss per Common Share
Net Loss per Common Share

Basic net loss per common share is computed by dividing the net loss before deemed dividend by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding and potentially outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through stock options, warrants, convertible preferred stock and convertible debentures. Due to the net loss for the period, such amounts were excluded from the diluted loss since their effect was considered anti-dilutive.

The table below shows the number of outstanding stock options and warrants as of September 30, 2019 and 2018:

September 30, 2019 September 30, 2018

Number of Shares Number of Shares

Stock Options 7,250,000 5,150,000

Warrants 171,833,216 216,441,548

Total 179,083,216 221,591,548

Recent accounting pronouncements
Recent accounting pronouncements

The Company considers the applicability and impact of all Accounting Standard Updates (“ASU’s”). ASU’s not discussed below were assessed and determined to be either not applicable or expected to have minimal impact on our balance sheets or statement of operations.

In June 2018, the FASB issued ASU 2018-07, “Compensation – Stock Compensation (Topic 718): Improvements to Non-employee Share-Based Accounting”. This guidance aligns the accounting for share-based payment transactions with non-employees to accounting for share-based payment transactions with employees. Companies are required to record a cumulative-effect adjustment (net of tax) to retained earnings as of the beginning of the fiscal year of the adoption. Upon transition, non-employee awards are required to be measured at fair value as of the adoption date. This standard will be effective for fiscal years beginning December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. The Company has adopted this ASU as of July 1, 2019. There has been no impact on the financial statements.

In August 2018, the FASB issued ASU 2018-13, “Fair value measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement”. The new guidance modifies the disclosure requirements on fair value measurements. ASU 2018-13 is effective for fiscal years beginning after December 15, 2019. Early adoption is permitted. The Company does not expect ASU 2018-13 to have a significant impact to its condensed consolidated financial statements and related disclosures.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ References
No definition available.
+ Details

Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257
+ Details

Name: us-gaap_EarningsPerSharePolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 37 R2.htm IDEA: XBRL DOCUMENT v3.19.3

Condensed Balance Sheet (Unaudited) - USD ($)

Sep. 30, 2019

Jun. 30, 2019

CURRENT ASSETS:

Cash $ 249,009 $ 339,923

Other Assets 516,379 334,150

Total Current Assets 765,388 674,073

OTHER ASSETS:

Intangible Assets 1,497,259 1,554,603

Goodwill 345,711 345,711

Total Fixed Assets 1,842,970 1,900,314

TOTAL ASSETS 2,608,358 2,574,387

CURRENT LIABILITIES:

Accounts Payable and accrued expenses 684,060 443,480

Derivative liability - warrants 8,109,724

Derivative liability - conversion option on convertible debenture 2,533,668

Convertible debenture - related party, net of discount $498,466 and $0 at September 30, 2019 and 2018, respectively 1,534

Total Current Liabilities 11,328,986 443,480

TOTAL LIABILITIES 11,328,986 443,480

Commitments and contingencies

STOCKHOLDERS' EQUITY

Preferred stock; $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding

Common stock, $0.0001 par value; 800,000,000 shares authorized at September 30, 2019 and June 30, 2019, respectively; 647,930,147 and 507,305,147 shares issued and outstanding at September 30, 2019 and June 30, 2019, respectively 64,793 50,730

Additional paid in capital 19,396,936 9,342,249

Accumulated deficit (28,182,357) (7,262,072)

Total Stockholders' Equity (8,720,628) 2,130,907

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 2,608,358 $ 2,574,387

X

- Definition
Convertible debenture - related party
+ References
No definition available.
+ Details

Name: bivi_ConvertibleDebentureRelatedParty

Namespace Prefix: bivi_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Derivative liability - conversion option on convertible debenture
+ References
No definition available.
+ Details

Name: bivi_DerivativeLiabilitiesConversionOptionCurrent

Namespace Prefix: bivi_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Derivative liability - warrants
+ References
No definition available.
+ Details

Name: bivi_DerivativeLiabilitiesWarrantCurrent

Namespace Prefix: bivi_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AdditionalPaidInCapitalCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910
+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.9)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765
+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(11))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(12))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(15))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(17))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(13))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(16))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(14))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(10))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsNoncurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 210
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 210
-Section 45
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840
+ Details

Name: us-gaap_Cash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.(a),19)
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.17)
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349
+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266
+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph ((a)(1),(b))
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274
+ Details

Name: us-gaap_IntangibleAssetsNetExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19-26)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(23))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(25))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(32))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current assets classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.8)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 38 R6.htm IDEA: XBRL DOCUMENT v3.19.3

Condensed Statements of Stockholders' Equity (Unaudited) - USD ($)

Preferred Stock

Common Stock

Additional Paid-In Capital

Accumulated Deficit

Total

Beginning Balance at Jun. 30, 2018 $ 9,850 $ 4,870,474 $ (4,769,126) $ 111,199

Beginning Balance, Shares at Jun. 30, 2018 98,503,199

Issuance of shares in a private placement $ 3,200,000 3,200,000 3,200,000

Issuance of shares in a private placement (in shares) 2,133,332

Conversion of preferred stock to common stock $ (3,200,000) $ 21,333 (21,333)

Conversion of preferred stock to common stock (in shares) (2,133,332) 213,333,200

Issuance of shares in exchange for debt settlement $ 98 1,150,037 1,150,135

Issuance of shares in exchange for debt settlement, Shares 975,361

Stock option compensation 3,412 3,412

Cashless exercise of warrants $ 224 (224)

Cashless exercise of warrants, Shares 2,241,913

Deemed dividends for ratchet adjustment to warrants 48,659 (48,659)

Net loss (439,871) (439,871)

Ending Balance at Sep. 30, 2018 $ 31,505 9,251,025 (5,257,655) 4,024,876

Ending Balance, Shares at Sep. 30, 2018 315,053,673

Beginning Balance at Jun. 30, 2019 $ 50,730 9,342,249 (7,262,072) 2,130,907

Beginning Balance, Shares at Jun. 30, 2019 507,305,147

Issuance of commitment shares $ 14,063 10,054,687 10,068,750

Issuance of commitment shares, Shares 140,625,000

Issuance of shares in exchange for debt settlement

Stock option compensation

Cashless exercise of warrants

Deemed dividends for ratchet adjustment to warrants (17,099,058) (17,099,058)

Net loss (3,821,227) (3,821,227)

Ending Balance at Sep. 30, 2019 $ 64,793 $ 19,396,936 $ (28,182,357) $ (8,720,628)

Ending Balance, Shares at Sep. 30, 2019 647,930,147

X

- Definition
Cashless Exercise of Warrants.
+ References
No definition available.
+ Details

Name: bivi_CashlessExerciseOfWarrants

Namespace Prefix: bivi_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Cashless Exercise of Warrants Shares
+ References
No definition available.
+ Details

Name: bivi_CashlessExerciseOfWarrantsShares

Namespace Prefix: bivi_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Conversion Of Preferred Stock To Common Stock.
+ References
No definition available.
+ Details

Name: bivi_ConversionOfPreferredStockToCommonStock

Namespace Prefix: bivi_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Conversion Of Preferred Stock To Common Stock (in shares)
+ References
No definition available.
+ Details

Name: bivi_ConversionOfPreferredStockToCommonStockInShares

Namespace Prefix: bivi_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Deemed Dividends for Ratchet Adjustment to Warrant
+ References
No definition available.
+ Details

Name: bivi_DeemedDividendsForRatchetAdjustmentToWarrants

Namespace Prefix: bivi_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Issuance Of Preferred Stock In Private Placement
+ References
No definition available.
+ Details

Name: bivi_IssuanceOfPreferredStockInPrivatePlacement

Namespace Prefix: bivi_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Issuance Of Preferred Stock In Private Placement (in shares)
+ References
No definition available.
+ Details

Name: bivi_IssuanceOfPreferredStockInPrivatePlacementInShares

Namespace Prefix: bivi_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Settlement Of Debt By Issuance Of Common Stock
+ References
No definition available.
+ Details

Name: bivi_SettlementOfDebtByIssuanceOfCommonStock

Namespace Prefix: bivi_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Settlement of Debt by Issuance of Common Stock, Shares
+ References
No definition available.
+ Details

Name: bivi_SettlementOfDebtByIssuanceOfCommonStockShares

Namespace Prefix: bivi_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686
+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of noncash expense for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Number of shares issued which are neither cancelled nor held in the treasury.
+ References
No definition available.
+ Details

Name: us-gaap_SharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of stock issued attributable to transactions classified as other.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesOther

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Value of shares of stock issued attributable to transactions classified as other.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4I
-URI http://asc.fasb.org/extlink&oid=116874947&loc=SL4590271-111686

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683
+ Details

Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 39 R13.htm IDEA: XBRL DOCUMENT v3.19.3

Equity Transactions
3 Months Ended

Sep. 30, 2019

Share-based Payment Arrangement [Abstract]

Equity Transactions

7. Equity Transactions

Stock Options

The following table summarizes the activity relating to the Company’s stock options for the three months ended September 30, 2019:

Options Weighted-Average Exercise Price Weighted Remaining Average Contractual Term Aggregate Intrinsic Value

Outstanding at June 30, 2019 7,250,000 $ 0.10 5.2 $ 87,480

Granted —   —   —   —

Options Exercised or Forfeited —   —   —   —

Outstanding at September 30, 2019 7,250,000 $ 0.10 4.8 $ 87,480

Exercisable at  September 30, 2019 7,250,000 $ 0.10 4.8 $ 87,480

The fair value of each option grant on the date of grant is estimated using the Black-Scholes option. There were no options granted during the three months ended September 30, 2019. The pricing model reflected the following weighted-average assumptions for the three months ended September 30, 2018:

September 30 2019 September 30 2018

Expected life of options (In years) —   9.5

Expected volatility —   63.09 %

Risk free interest rate —   0.00 %

Dividend Yield —   0 %

Expected volatility is based on the historical volatilities of three comparable companies of the daily closing price of their respective common stock and the expected life of options is based on historical data with respect to employee exercise periods. The Company accounts for forfeitures as they are incurred.

The Company recorded stock-based compensation expense of $0 and $3,412 for the three- month period ended September 30, 2019 and 2018, respectively.

The following is a summary of stock options outstanding and exercisable by exercise price as of September 30, 2019:

Exercise Price Outstanding Weighted Average Contract Life Exercisable

$ 0.03 700,000 4.3 700,000

$ 0.05 1,300,000 4.4 1,300,000

$ 0.06 3,100,000 6.4 3,100,000

$ 0.07 100,000 4.0 100,000

$ 0.10 500,000 3.3 500,000

$ 0.20 200,000 3.0 200,000

$ 0.21 550,000 2.6 550,000

$ 0.22 100,000 2.5 100,000

$ 0.23 200,000 2.9 200,000

$ 0.25 500,000 2.1 500,000

Total 7,250,000 7,250,000

Stock Warrants

The following table summarizes the warrants activity during the three months ended September 30, 2019:

Number of Shares Weighted Average Exercise Price Weighted Average Remaining Life (Years) Aggregate Intrinsic Value

Outstanding and exercisable at June 30, 2019 15,583,216 $ 0.36 5.6 $ 716,653

Granted 156,250,000 $ 0.03 5.0 $ 5,906,250

Expired —   $ —   —   $ —

Outstanding and exercisable at September 30, 2019 171,833,216 $ 0.04 4.9 $ 6,622,903

Of the above warrants, 1,173,864 expire in fiscal year ending June 30, 2022, 556,818 expire in fiscal year ending June 30, 2023, and 170,102,534 expire in fiscal year ending June 30, 2025.

X

- Definition
The entire disclosure for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-URI http://asc.fasb.org/topic&trid=2228938
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 40 R17.htm IDEA: XBRL DOCUMENT v3.19.3

Significant Accounting Policies (Tables)
3 Months Ended

Sep. 30, 2019

Disclosure Significant Accounting Policies Tables Abstract

Schedule of Dilutive securities were excluded from the computation of diluted loss per share
The table below shows the number of outstanding stock options and warrants as of September 30, 2019 and 2018:

September 30, 2019 September 30, 2018

Number of Shares Number of Shares

Stock Options 7,250,000 5,150,000

Warrants 171,833,216 216,441,548

Total 179,083,216 221,591,548

X

- References
No definition available.
+ Details

Name: bivi_DisclosureSignificantAccountingPoliciesTablesAbstract

Namespace Prefix: bivi_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 41 R3.htm IDEA: XBRL DOCUMENT v3.19.3

Condensed Balance Sheet (Unaudited) (Parenthetical) - $ / shares

Sep. 30, 2019

Jun. 30, 2019

Statement of Financial Position [Abstract]

Preferred stock, par value $ 0.001 $ 0.001

Preferred stock, shares authorized 10,000,000 10,000,000

Preferred Stock, Shares Issued 0 0

Preferred stock, shares outstanding 0 0

Common stock, par value $ 0.0001 $ 0.0001

Common stock, shares authorized 800,000,000 800,000,000

Common Stock Shares Issued 647,930,147 507,305,147

Common stock, shares outstanding 647,930,147 507,305,147

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfFinancialPositionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 42 R7.htm IDEA: XBRL DOCUMENT v3.19.3

Background Information
3 Months Ended

Sep. 30, 2019

Notes to Financial Statements

Background Information

1. Background Information

BioVie Inc. (the “Company”) is a clinical-stage company pursuing the discovery, development, and commercialization of innovative drug therapies. We are currently focused on developing and commercializing BIV201 (continuous infusion terlipressin), a novel approach to the treatment of ascites due to chronic liver cirrhosis. Our therapy BIV201 is based on a drug that is approved in about 40 countries to treat related complications of liver cirrhosis (part of the same disease pathway as ascites), but not yet available in the United States. BIV201’s active agent is a potent vasoconstrictor and has shown efficacy for reducing portal hypertension in studies around the world. The goal is for BIV201 to interrupt the ascites disease pathway, thereby halting the cycle of accelerating fluid generation in ascites patients.

BioVie began administering BIV201 to patients in a Phase 2a clinical trial in patients with refractory ascites due to advanced liver cirrhosis at the McGuire Research Institute Inc. in Richmond, VA in September 2017. In April 2019, we announced top-line results and in June met with representatives of the FDA for a Type C Guidance Meeting to discuss the study results and plan our next clinical study. In July 2019, the FDA provided meeting minutes that documented general agreement with the Company’s proposed randomized and controlled study design. The FDA also provided its suggestions and guidance regarding primary and secondary endpoints, quality of life measures and other key aspects of the clinical trial design. In October 2019, BioVie announced the submission of a Phase 2b/3 clinical trial protocol to the FDA. We are developing a patent-pending novel liquid formulation of terlipressin for use in this study that is intended to improve convenience for outpatient administration and avoid potential formulation errors that may occur when pharmacists reconstitute the powder version.

BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, nonalcoholic steatohepatitis (NASH), and alcoholism. It has FDA Fast-Track status and Orphan Drug designation for the most common of these complications, ascites, which represents a significant unmet medical need. An Orphan drug that is first-to-market typically receives 7 years of market exclusivity in the United States for the designated use(s). The FDA has never approved any drug specifically for treating ascites. In addition, the Company has a pending patent application directed to proprietary liquid formulations of terlipressin for use in its planned Phase 2b/3 trial, subject to FDA clearance, which could eventually provide up to 20 years of patent coverage in each country in which the Company seeks patent protection, such as the United States, if a patent issues according to the patent laws of the issuing country.

The BIV201 development program began at LAT Pharma LLC. On April 11, 2016, the Company acquired LAT Pharma LLC and the rights to its BIV201 development program. The Company currently owns all development and marketing rights to its drug candidate. The Company and PharmaIN, Corp. (“PharmaIN”), LAT Pharma’s former partner focused on the development of new modified drug candidates in the same therapeutic field but not including BIV201, had agreed to pay royalties equal to less than 1% of future net sales of each company's ascites drug development programs, or if such program is licensed to a third party, less than 5% of each company's net license revenues. On December 24, 2018, the Company returned its partial ownership rights to the PharmaIN modified terlipressin development program and simultaneously paid the remaining balance due on a related debt. PharmaIN, Corp.’s rights to our program remain unchanged.

The Company’s activities are subject to significant risks and uncertainties including failure to secure additional funding to properly execute the Company’s business plan.

X

- References
No definition available.
+ Details

Name: bivi_NotesToFinancialStatementsAbstract

Namespace Prefix: bivi_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-URI http://asc.fasb.org/topic&trid=2122149

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-URI http://asc.fasb.org/topic&trid=2197479
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 43 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 44 R21.htm IDEA: XBRL DOCUMENT v3.19.3

Significant Accounting Policies (Details) - shares
3 Months Ended

Sep. 30, 2019

Sep. 30, 2018

Dilutive Securities excluded from the Computation of Diluted Loss Per Share 179,083,216 221,591,548

Warrant [Member]

Dilutive Securities excluded from the Computation of Diluted Loss Per Share 171,833,216 216,441,548

Stock Option [Member]

Dilutive Securities excluded from the Computation of Diluted Loss Per Share 7,250,000 5,150,000

X

- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 45 R25.htm IDEA: XBRL DOCUMENT v3.19.3

Fair Value Measurements (Details 2)
3 Months Ended

Sep. 30, 2019

USD ($)

Balance at September 30, 2019 $ 10,643,392

Fair Value, Inputs, Level 3 [Member]

Balance at September 30, 2019 10,643,392

Derivative liability - Warrants [Member]

Balance at September 30, 2019 8,109,724

Derivative liability - Warrants [Member] | Fair Value, Inputs, Level 3 [Member]

Beginning balance at July 1, 2019

Additions to level 3 liabilities 8,367,012

Change in in fair value of level 3 liability (257,288)

Transfer in and/or out of Level 3

Balance at September 30, 2019 8,109,724

Derivative Liability - Conversion Option on Convertible Debenture [Member]

Balance at September 30, 2019 2,533,668

Derivative Liability - Conversion Option on Convertible Debenture [Member] | Fair Value, Inputs, Level 3 [Member]

Beginning balance at July 1, 2019

Additions to level 3 liabilities 2,638,966

Change in in fair value of level 3 liability (105,298)

Transfer in and/or out of Level 3

Balance at September 30, 2019 $ 2,533,668

X

- Definition
Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=118260190&loc=d3e13433-108611

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 20
-Section 55
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313
+ Details

Name: us-gaap_DerivativeLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of increase (decrease) of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of purchases of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of transfer of financial instrument classified as an asset into (out of) level 3 of the fair value hierarchy.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByBenchmarkAxis=bivi_DerivativeLiabilityWarrantsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ConcentrationRiskByBenchmarkAxis=bivi_DerivativeLiabilityConversionOptionOnConvertibleDebentureMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

Intangible Assets (Details) - USD ($)	Sep. 30, 2019	Jun. 30, 2019
Disclosure Intangible Assets Details Abstract
Intellectual Property	$ 2,293,770	$ 2,293,770
Accumulated Amortization	(796,511)	(739,167)
Intellectual Property, Net	$ 1,497,259	$ 1,554,603

Equity Transactions (Details) - Stock Option [Member] - USD ($)	3 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Option Outstanding at beginning of period	7,250,000
Option Granted
Option Exercised
Option Outstanding at end of period	7,250,000
Option Excersiable at end of period	7,250,000
Outstanding Weighted Average Exercise Price at the beginning of period	$ 0.10
Weighted Average Exercise Price, Granted
Weighted Average Exercise Price, Exercised
Outstanding Weighted Average Exercise Price at the end of period	0.10
Excersiable Weighted Average Exercise Price at the end of period	$ 0.10
Weighted Average Remaining Contractual Term at the beginning of period	5 years 2 months 12 days
Weighted Average Remaining Contractual Term at the end	4 years 9 months 18 days
Excersiable Weighted Average Remaining Contractual Term at the end of period	4 years 9 months 18 days
Aggregate Intrinsic Value Outstanding at beginning of period	$ 87,480
Granted
Options Exercised or Forfeited
Aggregate Intrinsic Value Outstanding at end of period	87,480
Aggregate Intrinsic Value Exercisable	$ 87,480
Expected life of options (In years)		9 years 6 months
Expected volatility		63.09%
Risk free interest rate		0.00%
Dividend Yield		0.00%

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
OPERATING EXPENSES
Amortization	$ 57,344	$ 57,344
Research and development expenses	341,501	194,521
Selling, general and administrative expenses	307,373	239,562
TOTAL OPERATING EXPENSES	706,218	491,427
LOSS FROM OPERATIONS	(706,218)	(491,427)
OTHER EXPENSE (INCOME)
Change in fair value of derivative liabilities	(362,586)
Gain on settlement of debt		(51,400)
Interest Expense	3,477,615	272
Interest income	(20)	(428)
TOTAL OTHER EXPENSE (INCOME)	3,115,009	(51,556)
NET LOSS	(3,821,227)	(439,871)
Deemed dividend	17,099,058	48,659
NET LOSS ATTRIBUTABLE TO COMPANY STOCKHOLDERS	$ (20,920,285)	$ (488,530)
NET LOSS PER COMMON SHARE, BASIC AND DILUTED	$ (0.04)	$ 0.00
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING, BASIC AND DILUTED	516,577,125	309,279,009

Fair Value Measurements (Details) - USD ($)	Sep. 30, 2019	Jun. 30, 2019
Total derivatives	$ 10,643,392
Fair Value, Inputs, Level 3 [Member]
Total derivatives	10,643,392
Derivative liability - Warrants [Member]
Total derivatives	8,109,724
Derivative liability - Warrants [Member] \| Fair Value, Inputs, Level 3 [Member]
Total derivatives	8,109,724
Derivative Liability - Conversion Option on Convertible Debenture [Member]
Total derivatives	2,533,668
Derivative Liability - Conversion Option on Convertible Debenture [Member] \| Fair Value, Inputs, Level 3 [Member]
Total derivatives	$ 2,533,668

Equity Transactions (Details 3) - Warrant [Member]	3 Months Ended
Equity Transactions (Details 3) - Warrant [Member]	Sep. 30, 2019 USD ($) $ / shares shares
Warrant Outstanding at the beginning of the year \| shares	15,583,216
Warrant Granted \| shares	156,250,000
Warrant Expired \| shares
Warrant Exercised \| shares	171,833,216
Weighted Average Exercise Price at the beginning of the year \| $ / shares	$ 0.36
Weighted Average Exercise Price, Granted \| $ / shares	0.03
Weighted Average Exercise Price, Expired \| $ / shares
Weighted Average Exercise Price, Exercised \| $ / shares	$ 0.04
Weighted Average Remaining Life at the beginning of the year	5 years
Weighted Average Remaining Life, Granted	5 years 3 months 18 days
Weighted Average Remaining Life at the end of year	5 years 3 months 18 days
Aggregate Intrinsic Value Outstanding at beginning of period \| $	$ 716,653
Aggregate Intrinsic Value, Granted \| $	5,906,250
Aggregate Intrinsic Value Outstanding at end of period \| $	$ 6,622,903

Condensed Balance Sheet (Unaudited) - USD ($)	Sep. 30, 2019	Jun. 30, 2019
CURRENT ASSETS:
Cash	$ 249,009	$ 339,923
Other Assets	516,379	334,150
Total Current Assets	765,388	674,073
OTHER ASSETS:
Intangible Assets	1,497,259	1,554,603
Goodwill	345,711	345,711
Total Fixed Assets	1,842,970	1,900,314
TOTAL ASSETS	2,608,358	2,574,387
CURRENT LIABILITIES:
Accounts Payable and accrued expenses	684,060	443,480
Derivative liability - warrants	8,109,724
Derivative liability - conversion option on convertible debenture	2,533,668
Convertible debenture - related party, net of discount $498,466 and $0 at September 30, 2019 and 2018, respectively	1,534
Total Current Liabilities	11,328,986	443,480
TOTAL LIABILITIES	11,328,986	443,480
Commitments and contingencies
STOCKHOLDERS' EQUITY
Preferred stock; $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding
Common stock, $0.0001 par value; 800,000,000 shares authorized at September 30, 2019 and June 30, 2019, respectively; 647,930,147 and 507,305,147 shares issued and outstanding at September 30, 2019 and June 30, 2019, respectively	64,793	50,730
Additional paid in capital	19,396,936	9,342,249
Accumulated deficit	(28,182,357)	(7,262,072)
Total Stockholders' Equity	(8,720,628)	2,130,907
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 2,608,358	$ 2,574,387

Condensed Statements of Stockholders' Equity (Unaudited) - USD ($)	Preferred Stock	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Beginning Balance at Jun. 30, 2018		$ 9,850	$ 4,870,474	$ (4,769,126)	$ 111,199
Beginning Balance, Shares at Jun. 30, 2018		98,503,199
Issuance of shares in a private placement	$ 3,200,000		3,200,000		3,200,000
Issuance of shares in a private placement (in shares)	2,133,332
Conversion of preferred stock to common stock	$ (3,200,000)	$ 21,333	(21,333)
Conversion of preferred stock to common stock (in shares)	(2,133,332)	213,333,200
Issuance of shares in exchange for debt settlement		$ 98	1,150,037		1,150,135
Issuance of shares in exchange for debt settlement, Shares		975,361
Stock option compensation			3,412		3,412
Cashless exercise of warrants		$ 224	(224)
Cashless exercise of warrants, Shares		2,241,913
Deemed dividends for ratchet adjustment to warrants			48,659	(48,659)
Net loss				(439,871)	(439,871)
Ending Balance at Sep. 30, 2018		$ 31,505	9,251,025	(5,257,655)	4,024,876
Ending Balance, Shares at Sep. 30, 2018		315,053,673
Beginning Balance at Jun. 30, 2019		$ 50,730	9,342,249	(7,262,072)	2,130,907
Beginning Balance, Shares at Jun. 30, 2019		507,305,147
Issuance of commitment shares		$ 14,063	10,054,687		10,068,750
Issuance of commitment shares, Shares		140,625,000
Issuance of shares in exchange for debt settlement
Stock option compensation
Cashless exercise of warrants
Deemed dividends for ratchet adjustment to warrants				(17,099,058)	(17,099,058)
Net loss				(3,821,227)	(3,821,227)
Ending Balance at Sep. 30, 2019		$ 64,793	$ 19,396,936	$ (28,182,357)	$ (8,720,628)
Ending Balance, Shares at Sep. 30, 2019		647,930,147

Condensed Balance Sheet (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2019	Jun. 30, 2019
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred Stock, Shares Issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	800,000,000	800,000,000
Common Stock Shares Issued	647,930,147	507,305,147
Common stock, shares outstanding	647,930,147	507,305,147

Significant Accounting Policies (Details) - shares	3 Months Ended
Significant Accounting Policies (Details) - shares	Sep. 30, 2019	Sep. 30, 2018
Dilutive Securities excluded from the Computation of Diluted Loss Per Share	179,083,216	221,591,548
Warrant [Member]
Dilutive Securities excluded from the Computation of Diluted Loss Per Share	171,833,216	216,441,548
Stock Option [Member]
Dilutive Securities excluded from the Computation of Diluted Loss Per Share	7,250,000	5,150,000

Fair Value Measurements (Details 2)	3 Months Ended
Fair Value Measurements (Details 2)	Sep. 30, 2019 USD ($)
Balance at September 30, 2019	$ 10,643,392
Fair Value, Inputs, Level 3 [Member]
Balance at September 30, 2019	10,643,392
Derivative liability - Warrants [Member]
Balance at September 30, 2019	8,109,724
Derivative liability - Warrants [Member] \| Fair Value, Inputs, Level 3 [Member]
Beginning balance at July 1, 2019
Additions to level 3 liabilities	8,367,012
Change in in fair value of level 3 liability	(257,288)
Transfer in and/or out of Level 3
Balance at September 30, 2019	8,109,724
Derivative Liability - Conversion Option on Convertible Debenture [Member]
Balance at September 30, 2019	2,533,668
Derivative Liability - Conversion Option on Convertible Debenture [Member] \| Fair Value, Inputs, Level 3 [Member]
Beginning balance at July 1, 2019
Additions to level 3 liabilities	2,638,966
Change in in fair value of level 3 liability	(105,298)
Transfer in and/or out of Level 3
Balance at September 30, 2019	$ 2,533,668